cd /home/daytona/workspace && python3 -c " import pdfplumber pdf_path = '/home/daytona/workspace/attachments/a8002ecc-58aa-475e-a59b-39af45eb6c4f/Chapter_56_PDF_pages_87-110.pdf' with pdfplumber.open(pdf_path) as pdf: print(f'Total pages: {len(pdf.pages)}') full_text = '' for i, page in enumerate(pdf.pages): text = page.extract_text() if text: full_text += f'\n\n--- PAGE {i+1} ---\n' + text print(full_text[:8000]) " 2>&1

cd /home/daytona/workspace && python3 -c " import pdfplumber pdf_path = '/home/daytona/workspace/attachments/a8002ecc-58aa-475e-a59b-39af45eb6c4f/Chapter_56_PDF_pages_87-110.pdf' with pdfplumber.open(pdf_path) as pdf: full_text = '' for i, page in enumerate(pdf.pages): text = page.extract_text() if text: full_text += f'\n\n--- PAGE {i+1} ---\n' + text with open('/home/daytona/workspace/chapter56_full.txt', 'w') as f: f.write(full_text) print(f'Total chars: {len(full_text)}') print(full_text[8000:16000]) " 2>&1

cat /home/daytona/workspace/chapter56_full.txt | wc -c && python3 -c " with open('/home/daytona/workspace/chapter56_full.txt') as f: text = f.read() print(text[16000:32000]) " 2>&1

python3 -c " with open('/home/daytona/workspace/chapter56_full.txt') as f: text = f.read() print(text[32000:56000]) " 2>&1

python3 -c " with open('/home/daytona/workspace/chapter56_full.txt') as f: text = f.read() print(text[56000:80000]) " 2>&1

python3 -c " with open('/home/daytona/workspace/chapter56_full.txt') as f: text = f.read() print(text[80000:]) " 2>&1

mkdir -p /home/daytona/workspace/ini_ss_ch56 && python3 << 'PYEOF' from reportlab.lib.pagesizes import A4 from reportlab.lib.styles import getSampleStyleSheet, ParagraphStyle from reportlab.lib.units import cm, mm from reportlab.lib.colors import HexColor, black, white, Color from reportlab.platypus import (SimpleDocTemplate, Paragraph, Spacer, Table, TableStyle, PageBreak, HRFlowable, KeepTogether) from reportlab.lib.enums import TA_CENTER, TA_LEFT, TA_JUSTIFY, TA_RIGHT from reportlab.platypus import Flowable import reportlab.lib.colors as colors # ── colour palette ────────────────────────────────────────────── NAVY = HexColor('#1a3a5c') TEAL = HexColor('#0a7c7c') ORANGE = HexColor('#e07b00') GOLD = HexColor('#f5c842') RED = HexColor('#c0392b') GREEN = HexColor('#1a7a44') LTBLUE = HexColor('#dbeeff') LTGREEN = HexColor('#d4edda') LTRED = HexColor('#fde8e8') LTYELLOW= HexColor('#fff9e0') SILVER = HexColor('#f4f6f8') W, H = A4 def build_styles(): s = getSampleStyleSheet() base = dict(fontName='Helvetica', fontSize=9, leading=13, textColor=black) styles = { 'Title': ParagraphStyle('Title', fontName='Helvetica-Bold', fontSize=20, textColor=white, alignment=TA_CENTER, spaceAfter=4), 'SubTitle': ParagraphStyle('SubTitle', fontName='Helvetica', fontSize=11, textColor=LTBLUE, alignment=TA_CENTER, spaceAfter=2), 'H1': ParagraphStyle('H1', fontName='Helvetica-Bold', fontSize=13, textColor=white, spaceBefore=6, spaceAfter=4, leading=16), 'H2': ParagraphStyle('H2', fontName='Helvetica-Bold', fontSize=10.5, textColor=NAVY, spaceBefore=6, spaceAfter=3, leading=14), 'H3': ParagraphStyle('H3', fontName='Helvetica-Bold', fontSize=9.5, textColor=TEAL, spaceBefore=4, spaceAfter=2, leading=13), 'Body': ParagraphStyle('Body', **base, alignment=TA_JUSTIFY, spaceAfter=4), 'Bullet': ParagraphStyle('Bullet', **base, leftIndent=12, spaceAfter=3, bulletIndent=4), 'Pearl': ParagraphStyle('Pearl', fontName='Helvetica-Bold', fontSize=9, textColor=NAVY, spaceAfter=3, leading=13), 'Small': ParagraphStyle('Small', fontName='Helvetica', fontSize=8, leading=11, textColor=black), 'SmallB': ParagraphStyle('SmallB', fontName='Helvetica-Bold', fontSize=8, leading=11, textColor=NAVY), 'Center': ParagraphStyle('Center', fontName='Helvetica', fontSize=9, leading=12, alignment=TA_CENTER), 'CenterB': ParagraphStyle('CenterB', fontName='Helvetica-Bold', fontSize=9, leading=12, alignment=TA_CENTER), 'Red': ParagraphStyle('Red', fontName='Helvetica-Bold', fontSize=9, textColor=RED, leading=13), 'Green': ParagraphStyle('Green', fontName='Helvetica-Bold', fontSize=9, textColor=GREEN, leading=13), } return styles def colored_header(text, bg=NAVY, fg=white, style_key='H1'): St = build_styles() p = Paragraph(text, St[style_key]) t = Table([[p]], colWidths=[17*cm]) t.setStyle(TableStyle([ ('BACKGROUND', (0,0), (-1,-1), bg), ('TOPPADDING', (0,0),(-1,-1), 5), ('BOTTOMPADDING', (0,0),(-1,-1), 5), ('LEFTPADDING', (0,0),(-1,-1), 8), ])) return t def info_box(title, items, bg=LTBLUE, title_bg=NAVY): """Box with title bar and bullet items.""" St = build_styles() rows = [[Paragraph(title, St['H1'])]] t_head = Table(rows, colWidths=[17*cm]) t_head.setStyle(TableStyle([ ('BACKGROUND',(0,0),(-1,-1), title_bg), ('TOPPADDING',(0,0),(-1,-1),4),('BOTTOMPADDING',(0,0),(-1,-1),4), ('LEFTPADDING',(0,0),(-1,-1),8), ])) body_rows = [[Paragraph('• ' + i, St['Bullet'])] for i in items] t_body = Table(body_rows, colWidths=[17*cm]) t_body.setStyle(TableStyle([ ('BACKGROUND',(0,0),(-1,-1), bg), ('TOPPADDING',(0,0),(-1,-1),2),('BOTTOMPADDING',(0,0),(-1,-1),2), ('LEFTPADDING',(0,0),(-1,-1),10), ('BOX',(0,0),(-1,-1),0.5,NAVY), ])) return [t_head, t_body, Spacer(1,4)] def two_col_table(headers, rows, col_widths=None, header_bg=NAVY): St = build_styles() if col_widths is None: col_widths = [8.5*cm, 8.5*cm] data = [[Paragraph(h, St['CenterB']) for h in headers]] for row in rows: data.append([Paragraph(str(c), St['Small']) for c in row]) t = Table(data, colWidths=col_widths) ts = TableStyle([ ('BACKGROUND',(0,0),(-1,0), header_bg), ('TEXTCOLOR',(0,0),(-1,0), white), ('ROWBACKGROUNDS',(0,1),(-1,-1),[white, SILVER]), ('GRID',(0,0),(-1,-1),0.4,colors.grey), ('TOPPADDING',(0,0),(-1,-1),3), ('BOTTOMPADDING',(0,0),(-1,-1),3), ('LEFTPADDING',(0,0),(-1,-1),4), ]) t.setStyle(ts) return t # ════════════════════════════════════════════════════════════════ # PDF 1 – HIGH YIELD TEACHING NOTES # ════════════════════════════════════════════════════════════════ def make_pdf1(): St = build_styles() doc = SimpleDocTemplate( '/home/daytona/workspace/ini_ss_ch56/PDF1_HighYield_Notes.pdf', pagesize=A4, leftMargin=1.8*cm, rightMargin=1.8*cm, topMargin=1.8*cm, bottomMargin=1.8*cm ) story = [] # ── Cover banner ────────────────────────────────────────────── cover = Table([[ Paragraph('INI SS CET – CVTS', ParagraphStyle('ct', fontName='Helvetica-Bold', fontSize=14, textColor=GOLD, alignment=TA_CENTER)), Paragraph('CHAPTER 56: INTERVENTIONAL CARDIOLOGY', ParagraphStyle('ct2', fontName='Helvetica-Bold', fontSize=16, textColor=white, alignment=TA_CENTER)), Paragraph('High Yield Teaching Notes | Landmark Trials | Memory Aids | Exam Pearls', ParagraphStyle('ct3', fontName='Helvetica', fontSize=10, textColor=LTBLUE, alignment=TA_CENTER)), ]], colWidths=[17*cm]) cover.setStyle(TableStyle([ ('BACKGROUND',(0,0),(-1,-1),NAVY), ('TOPPADDING',(0,0),(-1,-1),10),('BOTTOMPADDING',(0,0),(-1,-1),10), ('LEFTPADDING',(0,0),(-1,-1),8), ('SPAN',(0,0),(-1,-1)), ])) story.append(cover) story.append(Spacer(1,8)) # ───────────────────────────────────────────────────────────── # PAGE 1: OVERVIEW, HISTORY, ACCESS SITES, PCI INDICATIONS # ───────────────────────────────────────────────────────────── story.append(colored_header('PAGE 1: HISTORY, ACCESS SITES & PCI INDICATIONS', NAVY)) story.append(Spacer(1,4)) # History timeline table story.append(Paragraph('HISTORICAL MILESTONES (HIGH FREQUENCY EXAM TOPIC)', St['H2'])) hist_data = [ ['Year', 'Milestone', 'Key Person'], ['1964', 'First endovascular arterial dilation', 'Charles Dotter'], ['1974', 'First peripheral balloon angioplasty', 'Andreas Gruentzig'], ['Sep 1977', 'First PTCA (human coronary) – Birth of Interventional Cardiology', 'Andreas Gruentzig'], ['1994', 'Balloon-expandable stent (Palmaz-Schatz) approved after BENESTENT & STRESS trials', 'FDA/Palmaz'], ['2004', 'Drug-eluting stents (DES) FDA approved – sirolimus (Cypher) & paclitaxel (TAXUS)', 'FDA'], ['2017', 'ABSORB BVS withdrawn from all markets (higher complication rates)', '-'], ] t = two_col_table(['Year', 'Milestone', 'Key Person'], hist_data[1:], col_widths=[2.5*cm, 10*cm, 4.5*cm]) story.append(t) story.append(Spacer(1,5)) # Access sites story.append(Paragraph('VASCULAR ACCESS SITES', St['H2'])) access_data = [ ['Feature', 'Radial', 'Femoral'], ['Current use (USA)', '~50% & increasing', 'Traditional default'], ['Vascular complications', 'REDUCED ✓', 'Higher (1-5% hematoma, 1% pseudoaneurysm)'], ['Patient satisfaction', 'Higher ✓', 'Lower'], ['Radiation / procedure time', 'Slightly longer', 'Shorter'], ['Preferred in STEMI', 'YES ✓ (better outcomes)', 'Acceptable alternative'], ['Limitations', 'Small artery, tortuosity, operator learning curve', 'Larger sheath size acceptable'], ['Contraindication', 'Small artery, raynaud\'s, AV fistula for dialysis', 'Severe PVD, obesity'], ] t2 = two_col_table(['Feature','Radial','Femoral'], access_data[1:], col_widths=[4*cm, 6.5*cm, 6.5*cm]) story.append(t2) story.append(Spacer(1,5)) # PCI indications flowchart-style story.append(Paragraph('PCI INDICATIONS – DECISION FLOWCHART', St['H2'])) flow_data = [ ['Clinical Scenario', 'Strategy', 'Time Target / Guideline'], ['STEMI', 'Primary PCI (preferred over thrombolysis)', 'Door-to-balloon ≤90 min; ≤120 min if transfer needed'], ['STEMI – failed thrombolysis (30-50%)', 'Rescue PCI', 'Improves outcomes vs thrombolysis alone'], ['STEMI + cardiogenic shock', 'Immediate PCI or CABG (SHOCK trial)', 'Exception: age >75 – may not benefit'], ['UA/NSTEMI – moderate/high risk', 'Early invasive strategy (PCI within 24-48h)', 'ACC/AHA Class I'], ['Stable angina – refractory to meds', 'Elective PCI if viable myocardium at risk', 'COURAGE/ISCHEMIA: PCI ≠ mortality benefit'], ['LMCA (SYNTAX ≤22, ostial)', 'PCI = reasonable (Class IIa)', 'EXCEL trial: similar outcomes at 5 years'], ['LMCA (high SYNTAX ≥33)', 'CABG preferred (Class I)', 'SYNTAX: CABG superior'], ['3-vessel disease + Diabetes', 'CABG preferred', 'FREEDOM trial: CABG 18.7% vs PCI 26.6% MACE'], ] t3 = two_col_table(['Clinical Scenario','Strategy','Time Target / Guideline'], flow_data[1:], col_widths=[4.5*cm, 6*cm, 6.5*cm]) story.append(t3) story.append(Spacer(1,5)) # Exam pearl box pearl_items = [ 'First PTCA performed September 1977 by Gruentzig – THIS IS THE BIRTH OF INTERVENTIONAL CARDIOLOGY', 'Radial access → less vascular complications, better outcomes in STEMI', 'Primary PCI superior to thrombolysis if door-to-balloon ≤90 min (120 min if transfer)', 'Facilitated PCI (thrombolysis + immediate PCI) = HARMFUL; Pharmacoinvasive = ACCEPTABLE', 'SHOCK trial: Cardiogenic shock → immediate revascularization improves survival at 6 & 12 months EXCEPT age >75', 'COURAGE & ISCHEMIA trials: Stable CAD – PCI + meds NOT superior to meds alone for mortality/MI', 'FREEDOM trial: Diabetics + multivessel disease → CABG superior to PCI regardless of SYNTAX score', 'SYNTAX score: 0-22 = low; 23-32 = intermediate; ≥33 = high; high score → prefer CABG', ] pearl_rows = [[Paragraph('⚡ EXAM PEARL', St['H1'])]] t_pearl = Table(pearl_rows, colWidths=[17*cm]) t_pearl.setStyle(TableStyle([ ('BACKGROUND',(0,0),(-1,-1),ORANGE), ('TOPPADDING',(0,0),(-1,-1),4),('BOTTOMPADDING',(0,0),(-1,-1),4), ('LEFTPADDING',(0,0),(-1,-1),8), ])) story.append(t_pearl) body_rows = [[Paragraph('• ' + i, St['Bullet'])] for i in pearl_items] t_pbody = Table(body_rows, colWidths=[17*cm]) t_pbody.setStyle(TableStyle([ ('BACKGROUND',(0,0),(-1,-1),LTYELLOW), ('TOPPADDING',(0,0),(-1,-1),2),('BOTTOMPADDING',(0,0),(-1,-1),2), ('LEFTPADDING',(0,0),(-1,-1),10), ('BOX',(0,0),(-1,-1),0.5,ORANGE), ])) story.append(t_pbody) story.append(PageBreak()) # ───────────────────────────────────────────────────────────── # PAGE 2: LANDMARK TRIALS, CABG vs PCI, COMPLICATIONS # ───────────────────────────────────────────────────────────── story.append(colored_header('PAGE 2: LANDMARK TRIALS & COMPLICATIONS', TEAL)) story.append(Spacer(1,4)) story.append(Paragraph('LANDMARK TRIALS – QUICK REVISION TABLE', St['H2'])) trials = [ ['Trial', 'Comparison', 'Key Finding'], ['BARI', 'PTCA vs CABG (multivessel)', '5-yr survival similar; CABG better in diabetics (mortality 19.4% CABG vs 34.5% PTCA)'], ['SYNTAX', 'Paclitaxel DES vs CABG (3-vessel/LM)', 'CABG superior at 3 & 5 yrs (37.3% vs 26.9% MACE); Low SYNTAX score = similar'], ['FREEDOM', 'DES vs CABG in diabetics', 'CABG better – 18.7% vs 26.6% MACE at 5 yrs; CABG regardless of SYNTAX score'], ['EXCEL', 'PCI vs CABG for LMCA disease', 'No difference in death/stroke/MI at 5 yrs for low-intermediate SYNTAX; PCI more repeat revascularization'], ['COURAGE', 'PCI+meds vs meds alone (stable CAD)', 'No difference in death/MI; PCI = faster angina relief only'], ['ISCHEMIA', 'PCI+meds vs meds alone (mod-severe ischemia)', 'No difference in CV death/MI/hospitalization'], ['SHOCK', 'Early revascularization vs medical stabilization (cardiogenic shock)', 'Improved survival at 6 & 12 months with revascularization (PCI or CABG)'], ['TAPAS', 'Manual thrombectomy vs PCI alone (STEMI)', 'Improved myocardial perfusion; 1-yr survival benefit'], ['TASTE', 'Thrombus aspiration vs PCI alone (STEMI)', 'NO reduction in mortality at 30 days or 1 year'], ['TOTAL', 'Manual thrombectomy vs PCI alone (N=10,732)', 'Similar MACE; INCREASED stroke risk with thrombectomy (0.7% vs 0.3%, P=.02) → NOW CLASS III'], ['AiMI', 'AngioJet rheolytic thrombectomy vs primary PCI', 'LARGER infarct size + higher mortality with mechanical thrombectomy → HARMFUL'], ['SAFER', 'PercuSurge GuardWire vs conventional in SVG PCI', '50% reduction in periprocedural MI with embolic protection'], ['IABP-SHOCK II', 'IABP vs standard care in cardiogenic shock', 'NO survival advantage (39.7% vs 41.3%)'], ['CRISP-AMI', 'IABP before PCI vs standard (anterior STEMI, no shock)', 'NO reduction in infarct size'], ['BCIS-1', 'Elective IABP before high-risk PCI vs no IABP', 'No benefit at 28 days; Long-term (51-month): lower all-cause mortality with IABP'], ['PROTECT II', 'Impella 2.5 vs IABP (high-risk PCI)', 'Impella: trend toward lower MACE at 90 days (reduction in repeat revascularization)'], ['COAPT', 'MitraClip vs medical therapy (secondary MR + HF)', 'MitraClip: lower HF hospitalization at 2 yrs (35.8% vs 67.9%) + reduced mortality (29.1% vs 46.1%)'], ['EVEREST II', 'MitraClip vs surgery (primary MR)', 'Surgery: better freedom from MR; MitraClip: lower 30-day adverse events (15% vs 48%)'], ['RESPECT/REDUCE/CLOSE', 'PFO closure vs medical therapy (cryptogenic stroke)', 'PFO closure SUPERIOR – reduces recurrent stroke; Amplatzer PFO occluder FDA approved'], ['C-PORT / MASS COMM', 'Primary PCI without on-site cardiac surgery', 'SAFE – non-inferior outcomes; Supports PCI at community hospitals (Class IIa)'], ] t4 = two_col_table(['Trial','Comparison','Key Finding'], trials[1:], col_widths=[2.8*cm, 5.2*cm, 9*cm], header_bg=TEAL) story.append(t4) story.append(Spacer(1,6)) story.append(Paragraph('COMPLICATIONS OF PCI', St['H2'])) comp_data = [ ['Complication', 'Rate', 'Key Facts'], ['Death (elective)', '<0.3%', 'Higher in: elderly, STEMI, ESRD, cardiogenic shock, EF reduction, SVG PCI'], ['Emergency CABG', '<1%', 'Pre-stent era: 3-5%; STS operative mortality >5% within 6h of PTCA'], ['Q-wave MI (peri-PCI)', '<1%', 'Myonecrosis (cTn rise) in up to 1/3; Definition: cTn >5x ULN within 48h'], ['Hematoma (femoral)', '1-5%', 'Pseudoaneurysm 1%; Retroperitoneal hemorrhage <1%'], ['Pseudoaneurysm management', '>', '>2 cm → US-guided thrombin injection (replaces surgery)'], ['Contrast-induced nephropathy', 'Variable', 'Prevent with NS hydration; N-acetylcysteine NOT recommended'], ['CIN risk factors', '-', 'Hypotension, IABP use, CHF, CKD, DM, age >75, anemia, high contrast volume'], ['Anaphylaxis from contrast', '1/55,000 death', 'Pretreat with steroids + diphenhydramine + use nonionic contrast in prior reactors'], ['Restenosis (BMS)', '10-30%', 'DES reduced to <10%; Risk: DM, small vessels, long lesions, bifurcations'], ['Stent thrombosis (DES vs BMS)', 'DES 0.6%, BMS 0.8%', 'Early (0-30d), Late (31-365d), Very late (>365d); DAPT critical'], ] t5 = two_col_table(['Complication','Rate','Key Facts'], comp_data[1:], col_widths=[4.2*cm, 2.5*cm, 10.3*cm], header_bg=RED) story.append(t5) story.append(PageBreak()) # ───────────────────────────────────────────────────────────── # PAGE 3: ADVANCED TECHNOLOGY – DES, ATHERECTOMY, IVUS, FFR # ───────────────────────────────────────────────────────────── story.append(colored_header('PAGE 3: ADVANCED TECHNOLOGY – DES, ATHERECTOMY, IVUS/OCT, FFR', GREEN)) story.append(Spacer(1,4)) story.append(Paragraph('DRUG-ELUTING STENTS (DES)', St['H2'])) des_data = [ ['Feature', 'Details'], ['FDA approval', '2004 – sirolimus (Cypher) & paclitaxel (TAXUS)'], ['Mechanism', 'Polymer coating releases anti-proliferative drugs → inhibit smooth muscle cell proliferation & neointimal hyperplasia'], ['Drugs used', 'Sirolimus, Paclitaxel (1st gen); Zotarolimus, Everolimus (2nd gen – safer)'], ['DES vs BMS restenosis', 'Reduced from 30% (BMS) to <10% (DES)'], ['Stent thrombosis concern', 'Very late thrombosis >365d (rare); Needs prolonged DAPT'], ['DAPT duration', 'BMS: minimum 1 month; DES: 12 months (high-bleeding risk: 1 month with Resolute Onyx – ONYX ONE CLEAR)'], ['Off-label DES use (FDA ~60%)', 'Bifurcations, ostial lesions, bypass grafts, >30mm lesion, vessels <2.5 or >3.75mm, LMCA, restenosis'], ['ABSORB BVS (bioresorbable)', 'HIGHER complications → withdrawn from ALL markets in 2017'], ['Current standard', 'DES used in ~80% of all PCIs in USA'], ['Surgery after stent', 'Avoid surgery <6 weeks post-stent (high risk); Discontinuing DAPT increases stent thrombosis risk'], ] t6 = two_col_table(['Feature','Details'], des_data[1:], col_widths=[5*cm, 12*cm], header_bg=GREEN) story.append(t6) story.append(Spacer(1,5)) story.append(Paragraph('ATHERECTOMY & LITHOTRIPSY DEVICES', St['H2'])) ath_items = [ 'Rotational atherectomy (PTCRA): Nickel-brass burr with diamond chips; 140,000-200,000 rpm; pulverizes plaque into 5-12 µm particles (cleared by reticuloendothelial system)', 'Orbital atherectomy: Eccentric diamond-coated burr; bidirectional; approved for peripheral AND coronary arteries', 'Intravascular lithotripsy (Shockwave): Pulsatile sonic pressure waves; circumferentially modifies vascular calcium', 'All 3 now used as "ENABLING DEVICES" – prepare calcified vessels for angioplasty/stenting', 'Directional atherectomy: NO LONGER AVAILABLE (high periprocedural MI)', 'Excimer laser: Not in general use; renewed interest for calcified lesions / diffuse in-stent restenosis', ] for item in ath_items: story.append(Paragraph('• ' + item, St['Bullet'])) story.append(Spacer(1,5)) story.append(Paragraph('IVUS vs OCT vs FFR – IMAGING & PHYSIOLOGY', St['H2'])) imaging_data = [ ['Feature', 'IVUS', 'OCT', 'FFR'], ['Modality', 'Intravascular ultrasound', 'Near-infrared light', 'Pressure wire'], ['Resolution', 'Lower', '10x higher than IVUS', 'Functional/physiologic'], ['Best use', 'LMCA assessment, stent expansion, plaque characterization', 'Calcium thickness, plaque type (fibrous/lipid/calcific), thrombus (white=platelet vs red=RBC), stent failure', 'Intermediate stenoses (25-70%)'], ['Limitation', '-', 'Requires blood clearing (10-15 mL contrast); difficult in LMCA', 'Requires adenosine for maximal hyperemia'], ['Cut-off value', 'N/A', 'N/A', '<0.80 = significant ischemia; ≥0.80 = can defer'], ['Guideline evidence', 'IVUS-guided stenting: lower MACE up to 5 years (HR 0.50)', 'OCT = IVUS equivalent for stent guidance', 'Superiority over IVUS for intermediate stenoses outside LMCA'], ] t7 = two_col_table(['Feature','IVUS','OCT','FFR'], imaging_data[1:], col_widths=[3.5*cm, 4.5*cm, 5*cm, 4*cm], header_bg=GREEN) story.append(t7) story.append(Spacer(1,5)) story.append(Paragraph('THROMBECTOMY – WHAT THE EXAMS WANT YOU TO KNOW', St['H2'])) thrombus_data = [ ['Trial', 'Outcome', 'Current Guideline'], ['TAPAS (manual)', 'Improved myocardial perfusion + 1-yr survival', 'Historical IIa'], ['INFUSE-AMI', 'Intracoronary abciximab reduced infarct; aspiration thrombectomy did NOT', '-'], ['TASTE (manual)', 'NO mortality reduction at 30d or 1 yr', 'Downgraded'], ['TOTAL (N=10,732)', 'Similar MACE; INCREASED stroke with thrombectomy (0.7% vs 0.3%)', 'CLASS III – DO NOT do routine aspiration thrombectomy in STEMI'], ['AiMI (mechanical/AngioJet)', 'LARGER infarct + higher mortality', 'HARMFUL in STEMI'], ['SAFER (distal protection)', '50% reduction in periprocedural MI in SVG PCI', 'Recommended for SVG PCI (Class I/IIa)'], ] t8 = two_col_table(['Trial','Outcome','Current Guideline'], thrombus_data[1:], col_widths=[3.5*cm, 8*cm, 5.5*cm], header_bg=RED) story.append(t8) story.append(PageBreak()) # ───────────────────────────────────────────────────────────── # PAGE 4: STRUCTURAL INTERVENTIONS # ───────────────────────────────────────────────────────────── story.append(colored_header('PAGE 4: STRUCTURAL / NON-CORONARY INTERVENTIONS', ORANGE)) story.append(Spacer(1,4)) story.append(Paragraph('BALLOON MITRAL VALVULOPLASTY (PMBV / BMV)', St['H2'])) bmv_data = [ ['Parameter', 'Details'], ['Introduced by', 'Inoue (1984) and Lock (1985)'], ['Mechanism', 'Fractures calcified leaflets + separates fused commissures via transseptal approach'], ['Result', 'MVA increases from <1.0 cm² to ~2.0 cm²; 50-60% decrease in transmitral gradient'], ['Class I indication (ACC/AHA 2014)', 'Symptomatic severe MS (MVA ≤1.5 cm²) + favorable morphology + NO LA thrombus + NO moderate-severe MR'], ['Class IIa', 'Asymptomatic very severe MS (MVA ≤1.0 cm²)'], ['Class IIb', 'Severe MS with new AF; hemodynamically significant MS on exercise; palliative in poor surgical candidates'], ['Wilkins score', 'Assesses: leaflet rigidity + thickness + calcification + subvalvular disease (score ≤8 = favorable)'], ['Contraindications', 'LA thrombus, moderate-severe MR, severe subvalvular/calcific disease, ostium primum defects'], ['Complications', 'Severe MR, ASD formation'], ['Outcomes vs surgery', 'PMBV ≥ closed commissurotomy; PMBV better than closed commissurotomy at 7-yr follow-up'], ['TEE before PMBV', 'Mandatory to exclude LA thrombus'], ] t9 = two_col_table(['Parameter','Details'], bmv_data[1:], col_widths=[5*cm, 12*cm], header_bg=ORANGE) story.append(t9) story.append(Spacer(1,5)) story.append(Paragraph('BALLOON AORTIC VALVULOPLASTY (BAV)', St['H2'])) bav_items = [ 'Mechanism: Fracture of calcific deposits + stretching of annulus; post-BAV valve area RARELY exceeds 1.0 cm²', 'Complications: Stroke (~2%), coronary occlusion (~0.5%), severe AR (~1%), vascular complications (>7%)', 'Restenosis within 6-12 months in MOST patients; NO impact on long-term survival', 'BAV is NOT a substitute for AVR / TAVR', 'ROLE OF BAV TODAY: Bridge to TAVR/surgical AVR in high-risk patients; urgent noncardiac surgery; low-output low-gradient AS to assess ventricular recovery; palliation in limited life expectancy', ] for item in bav_items: story.append(Paragraph('• ' + item, St['Bullet'])) story.append(Spacer(1,5)) story.append(Paragraph('MitraClip (PERCUTANEOUS MITRAL VALVE REPAIR)', St['H2'])) mitraclip_data = [ ['Feature', 'Details'], ['Device', 'MitraClip (Abbott) – cobalt chromium clip; mimics edge-to-edge Alfieri stitch'], ['Access', 'Femoral vein → transseptal puncture → attached to anterior + posterior leaflets'], ['FDA approved for', 'Primary MR (high surgical risk); Secondary MR (COAPT trial)'], ['EVEREST II', 'MitraClip vs surgery: surgery better for freedom from MR; MitraClip: lower 30-day adverse events (15% vs 48%), driven by surgical bleeding'], ['COAPT trial', 'Secondary MR + HF: MitraClip → HF hosp ↓ (35.8% vs 67.9%), mortality ↓ (29.1% vs 46.1%) at 2 yrs'], ['Indication (ACC/AHA 2014)', 'NYHA III/IV, chronic severe primary MR, reasonable life expectancy, prohibitive surgical risk'], ] t10 = two_col_table(['Feature','Details'], mitraclip_data[1:], col_widths=[5*cm, 12*cm], header_bg=ORANGE) story.append(t10) story.append(Spacer(1,5)) story.append(Paragraph('ALCOHOL SEPTAL ABLATION (ASA) FOR HOCM', St['H2'])) asa_items = [ 'Percutaneous obliteration of 1st or 2nd septal perforating artery using absolute alcohol → iatrogenic septal infarct → LVOT widening', 'Immediate results comparable to surgical myotomy/myectomy', 'Most common complication: Complete heart block → permanent pacemaker in 7-14% (up to 5 days post-procedure)', 'RBBB in >40%; Primary AV conduction abnormality in >50%', 'Risk of CHB INCREASED in patients with baseline LBBB (ablation targets basal septum near right bundle)', 'Procedural complication rate HIGHER than surgical myectomy; survival rates SIMILAR', 'Guidelines (ACC/AHA 2011): ASA only for patients who are POOR surgical candidates or DECLINE surgery', 'Transient heart block = COMMON; prophylactic pacing wire required', ] for item in asa_items: story.append(Paragraph('• ' + item, St['Bullet'])) story.append(Paragraph('PFO / ASD CLOSURE', St['H2'])) pfo_data = [ ['Feature', 'PFO Closure', 'ASD Closure'], ['Indication', 'Cryptogenic stroke with PFO (after failed medical therapy)', 'Qp:Qs ≥1.5, symptoms, RV dysfunction, embolism'], ['Evidence', 'CLOSURE I, PC, RESPECT (pooled: borderline) → RESPECT extended + REDUCE + CLOSE: CLEAR benefit', 'Observational: comparable to surgery'], ['Benefit', 'Amplatzer PFO occluder FDA approved; 5.1% vs 1.8% stroke (abs risk reduction 3.3%)', 'Similar procedural success; shorter LOS vs surgery'], ['Contraindications', 'No large right-to-left shunt features', 'Severe fixed pulmonary HTN, severe diastolic dysfunction, ostium primum, sinus venosus, large stretched diameter >38mm'], ['Who benefits most', 'Large right-to-left shunt + atrial septal aneurysm + increased paradoxical embolism risk', 'Qp:Qs ≥1.5 or symptomatic secundum ASD'], ] t11 = two_col_table(['Feature','PFO Closure','ASD Closure'], pfo_data[1:], col_widths=[4*cm, 6.5*cm, 6.5*cm], header_bg=NAVY) story.append(t11) story.append(PageBreak()) # ───────────────────────────────────────────────────────────── # PAGE 5: MECHANICAL CIRCULATORY SUPPORT + LAST MINUTE REVISION # ───────────────────────────────────────────────────────────── story.append(colored_header('PAGE 5: CIRCULATORY ASSIST DEVICES & LAST-MINUTE REVISION', RED)) story.append(Spacer(1,4)) story.append(Paragraph('PERCUTANEOUS CIRCULATORY ASSIST DEVICES', St['H2'])) devices_data = [ ['Device', 'Mechanism', 'Flow', 'Placement', 'Contraindications', 'Key Trial'], ['IABP', 'Counterpulsation – inflates in diastole (↑coronary flow) + deflates in systole (↓afterload)', '0.5-1 L/min', 'Femoral artery; helium-filled 25-50mL balloon', 'Aortic regurgitation, aortic dissection, severe PVD', 'IABP-SHOCK II: No survival benefit in cardiogenic shock; CRISP-AMI: No infarct size reduction'], ['Impella 2.5', 'Microaxial pump (Archimedes screw); LV → aorta', 'Up to 2.5 L/min', 'Femoral/axillary artery (13 Fr)', 'Aortic regurgitation, metallic aortic valve, LV/LA thrombus, severe PVD', 'PROTECT II: Impella > IABP in high-risk PCI (trend)'], ['Impella CP', 'Same as 2.5 but larger', 'Up to 4.0 L/min', 'Femoral/axillary (14 Fr)', 'Same as Impella 2.5', 'PROTECT III registry'], ['Impella 5.0/5.5', 'Same principle; larger', '~5 L/min', 'Axillary graft', 'Same', 'Approved up to 14 days'], ['Impella RP', 'Right-sided microaxial pump: IVC → PA, bypasses RV', 'Up to 5 L/min', 'Femoral vein; across tricuspid + pulmonic valves', 'Biventricular failure (→ LVAD), respiratory failure (→ ECMO)', 'RECOVER RIGHT prospective cohort'], ['TandemHeart', 'LA → femoral artery bypass; centrifugal pump', 'Up to 5 L/min; 7500 rpm', 'Femoral vein → transseptal to LA; arterial cannula', 'Similar to Impella', 'RCTs: Better hemodynamics than IABP in cardiogenic shock'], ['Protek Duo', 'RVAD; right IJV → PA; oxygenator option', 'Up to 5 L/min', 'Right IJV → PA', 'Biventricular failure', 'Small observational series; hemodynamic improvement'], ] t12 = two_col_table(['Device','Mechanism','Flow','Placement','Contraindications','Key Trial'], devices_data[1:], col_widths=[2*cm, 3.5*cm, 1.8*cm, 3*cm, 3.2*cm, 3.5*cm], header_bg=RED) story.append(t12) story.append(Spacer(1,5)) story.append(Paragraph('PHARMACOLOGY PEARLS – ANTIPLATELET / ANTICOAGULATION', St['H2'])) pharma_items = [ 'DAPT = aspirin + P2Y12 inhibitor (clopidogrel / ticagrelor / prasugrel)', 'BMS: minimum 1 month DAPT; DES: 12 months DAPT (standard)', 'High bleeding risk (Resolute Onyx DES): 1 month DAPT acceptable (ONYX ONE CLEAR study)', 'Before urgent CABG: Clopidogrel/ticagrelor → delay 5 days; Prasugrel → delay 7 days', 'GP IIb/IIIa inhibitors (abciximab/eptifibatide/tirofiban): Discontinue ≥2 hours before CABG', 'Abciximab: Platelet transfusion can reverse; Eptifibatide/tirofiban: Platelet transfusion USELESS', 'Thrombolysis + surgery within 12h: Increased bleeding, transfusion, reoperation', 'Anticoagulants during PCI: UFH, LMWH, or bivalirudin (direct thrombin inhibitor)', ] for item in pharma_items: story.append(Paragraph('• ' + item, St['Bullet'])) story.append(Spacer(1,5)) story.append(Paragraph('LAST-MINUTE REVISION TABLE', St['H2'])) rev_rows = [[Paragraph('QUICK REFERENCE – LAST MINUTE REVISION', St['H1'])]] t_rev = Table(rev_rows, colWidths=[17*cm]) t_rev.setStyle(TableStyle([ ('BACKGROUND',(0,0),(-1,-1),NAVY), ('TOPPADDING',(0,0),(-1,-1),4),('BOTTOMPADDING',(0,0),(-1,-1),4), ('LEFTPADDING',(0,0),(-1,-1),8), ])) story.append(t_rev) lm_data = [ ['Topic', 'Answer'], ['First PTCA date & person', 'September 1977, Andreas Gruentzig'], ['Door-to-balloon time STEMI', '≤90 min (≤120 min if transfer required)'], ['Primary PCI vs thrombolysis', 'PCI superior if time targets met'], ['Facilitated PCI', 'HARMFUL – NOT recommended'], ['Pharmacoinvasive strategy', 'Acceptable – fibrinolysis then PCI 3-24h later'], ['SHOCK trial lesson', 'Immediate revascularization (PCI/CABG) in cardiogenic shock – better survival; EXCEPT age >75'], ['COURAGE/ISCHEMIA lesson', 'Stable CAD: PCI + meds = meds alone for mortality/MI (PCI gives faster angina relief)'], ['SYNTAX score cut-offs', 'Low 0-22, Intermediate 23-32, High ≥33'], ['Diabetics + 3-vessel disease', 'CABG preferred (FREEDOM trial)'], ['LMCA PCI Class IIa', 'SYNTAX ≤22, ostial LMCA, or high surgical risk'], ['DES restenosis rate', '<10% (vs 10-30% BMS)'], ['Stent thrombosis classification', 'Early <30d; Late 31-365d; Very late >365d'], ['ABSORB BVS', 'Withdrawn 2017 – higher complications'], ['Routine thrombectomy in STEMI', 'CLASS III – NOT recommended (TOTAL trial – increased stroke)'], ['AngioJet in STEMI', 'HARMFUL – larger infarct (AiMI trial)'], ['Embolic protection in SVG PCI', 'RECOMMENDED (Class I/IIa) – SAFER trial: 50% ↓ periprocedural MI'], ['FFR cut-off', '<0.80 = significant ischemia; ≥0.80 = defer revascularization'], ['IVUS best use', 'LMCA assessment, stent guidance; 5-yr MACE reduction'], ['OCT limitation', 'Cannot use in LMCA (requires blood clearing with contrast)'], ['IABP in cardiogenic shock', 'NO survival benefit (IABP-SHOCK II)'], ['Impella RP indication', 'Right heart failure; IVC→PA bypass; NOT for biventricular failure (use LVAD)'], ['TandemHeart mechanism', 'LA → femoral artery; reduces LV preload; up to 5 L/min'], ['PMBV indication (Class I)', 'Symptomatic severe MS (MVA ≤1.5 cm²), favorable morphology, no LA thrombus, no significant MR'], ['Wilkins score', '≤8 = favorable for PMBV; accounts for rigidity, thickness, calcification, subvalvular disease'], ['BAV role today', 'Bridge to TAVR/AVR; NOT substitute for valve replacement'], ['ASA for HOCM', 'Only for poor/declined surgical candidates; CHB in 7-14%; worse procedural outcomes than myectomy'], ['MitraClip device', 'Edge-to-edge; femoral vein → transseptal; COAPT trial = secondary MR in HF → mortality ↓'], ['PFO closure indication', 'Cryptogenic stroke + PFO; Amplatzer FDA approved; abs risk reduction 3.3%'], ['ASD – NOT suitable for percutaneous', 'Ostium primum, sinus venosus, coronary sinus defects, stretched diam >38mm, rim <4mm'], ['Pseudoaneurysm management', '>2 cm → US-guided thrombin injection'], ['CIN prevention', 'NS hydration; NO N-acetylcysteine'], ['Clopidogrel before CABG', 'Wait 5 days; Prasugrel: 7 days'], ['PCI without on-site surgery', 'Safe – Class IIa; MASS COMM trial supports; need experienced operators + rapid transfer protocol'], ['Operator volume for good outcomes', '>75 cases/year; Hospital volume >200 PCI/year'], ] t_lm = two_col_table(['Topic','Answer'], lm_data[1:], col_widths=[7*cm, 10*cm], header_bg=NAVY) story.append(t_lm) # Memory aids story.append(Spacer(1,5)) story.append(Paragraph('MEMORY AIDS', St['H2'])) mem_rows = [[Paragraph('🧠 MNEMONICS & MEMORY AIDS', St['H1'])]] t_mem = Table(mem_rows, colWidths=[17*cm]) t_mem.setStyle(TableStyle([ ('BACKGROUND',(0,0),(-1,-1),TEAL), ('TOPPADDING',(0,0),(-1,-1),4),('BOTTOMPADDING',(0,0),(-1,-1),4), ('LEFTPADDING',(0,0),(-1,-1),8), ])) story.append(t_mem) mem_items = [ '"FREEDOM from Diabetes" → FREEDOM trial = Diabetics → CABG better than DES regardless of SYNTAX', '"SHOCKING" results for cardiogenic shock → SHOCK trial = immediate revascularization saves lives (EXCEPT >75 yrs)', '"TOTAL-ly no use" → TOTAL trial = routine thrombectomy in STEMI = Class III (harmful – stroke risk)', '"IABP II Shocks no one" → IABP-SHOCK II = IABP has NO survival benefit in cardiogenic shock', '"COAPT with a clip" → COAPT trial = MitraClip for secondary MR in HF → mortality benefit', '"PMBV prefers the YOUNG, PLIABLE, NON-CALCIFIED VALVE" = favorable Wilkins score ≤8', '"FFR 0.80 is the GO" → FFR ≥0.80 = DEFER (no ischemia); <0.80 = TREAT', '"ASA only for the UNsurgical" = Alcohol Septal Ablation only for HOCM patients who cannot/won\'t have surgery', '"RESPECT the PFO" → RESPECT extended trial confirms PFO closure reduces stroke; Amplatzer device FDA approved', ] mem_body = [[Paragraph('• ' + i, St['Bullet'])] for i in mem_items] t_membody = Table(mem_body, colWidths=[17*cm]) t_membody.setStyle(TableStyle([ ('BACKGROUND',(0,0),(-1,-1), HexColor('#e0f7f7')), ('TOPPADDING',(0,0),(-1,-1),2),('BOTTOMPADDING',(0,0),(-1,-1),2), ('LEFTPADDING',(0,0),(-1,-1),10), ('BOX',(0,0),(-1,-1),0.5,TEAL), ])) story.append(t_membody) doc.build(story) print('PDF1 done') make_pdf1() PYEOF echo "Exit: $?"

python3 << 'PYEOF' from reportlab.lib.pagesizes import A4 from reportlab.lib.styles import getSampleStyleSheet, ParagraphStyle from reportlab.lib.units import cm, mm from reportlab.lib.colors import HexColor, black, white from reportlab.platypus import (SimpleDocTemplate, Paragraph, Spacer, Table, TableStyle, PageBreak, HRFlowable) from reportlab.lib.enums import TA_CENTER, TA_LEFT, TA_JUSTIFY, TA_RIGHT import reportlab.lib.colors as colors NAVY = HexColor('#1a3a5c') TEAL = HexColor('#0a7c7c') ORANGE = HexColor('#e07b00') GOLD = HexColor('#f5c842') RED = HexColor('#c0392b') GREEN = HexColor('#1a7a44') LTBLUE = HexColor('#dbeeff') SILVER = HexColor('#f4f6f8') LTYELLOW= HexColor('#fff9e0') def S(name, **kw): base = { 'Title': ParagraphStyle('Title', fontName='Helvetica-Bold', fontSize=18, textColor=white, alignment=TA_CENTER, spaceAfter=2, leading=22), 'SubT': ParagraphStyle('SubT', fontName='Helvetica', fontSize=10, textColor=LTBLUE, alignment=TA_CENTER, spaceAfter=3), 'QNum': ParagraphStyle('QNum', fontName='Helvetica-Bold', fontSize=11, textColor=NAVY, spaceBefore=8, spaceAfter=4, leading=14), 'QBody': ParagraphStyle('QBody', fontName='Helvetica', fontSize=10, textColor=black, spaceAfter=3, leading=14, alignment=TA_JUSTIFY), 'Option': ParagraphStyle('Option', fontName='Helvetica', fontSize=10, textColor=black, spaceAfter=2, leading=13, leftIndent=8), 'Tag': ParagraphStyle('Tag', fontName='Helvetica-Bold', fontSize=8, textColor=white, spaceAfter=2, leading=10), 'Inst': ParagraphStyle('Inst', fontName='Helvetica-Oblique', fontSize=9, textColor=TEAL, spaceAfter=3, leading=12), 'Body': ParagraphStyle('Body', fontName='Helvetica', fontSize=9, textColor=black, spaceAfter=3, leading=13), 'Bold': ParagraphStyle('Bold', fontName='Helvetica-Bold', fontSize=9, textColor=black, spaceAfter=3, leading=13), 'H2': ParagraphStyle('H2', fontName='Helvetica-Bold', fontSize=10, textColor=NAVY, spaceBefore=5, spaceAfter=3, leading=13), 'Correct': ParagraphStyle('Correct', fontName='Helvetica-Bold', fontSize=10, textColor=GREEN, spaceAfter=2, leading=13), 'Distract':ParagraphStyle('Distract',fontName='Helvetica', fontSize=9, textColor=black, spaceAfter=3, leading=13, leftIndent=10), 'LP': ParagraphStyle('LP', fontName='Helvetica-Bold', fontSize=9, textColor=HexColor('#005500'), spaceAfter=2, leading=12), 'GL': ParagraphStyle('GL', fontName='Helvetica-Bold', fontSize=9, textColor=ORANGE, spaceAfter=2, leading=12), } return base[name] def colored_hdr(text, bg=NAVY, fg=white): p = Paragraph(text, ParagraphStyle('hdr', fontName='Helvetica-Bold', fontSize=12, textColor=fg, alignment=TA_CENTER)) t = Table([[p]], colWidths=[17*cm]) t.setStyle(TableStyle([ ('BACKGROUND',(0,0),(-1,-1),bg), ('TOPPADDING',(0,0),(-1,-1),6),('BOTTOMPADDING',(0,0),(-1,-1),6), ])) return t def q_box(num, tag_txt, tag_col, stem, options, instruction=''): """Build a question block.""" elems = [] # Question number + tag tag_p = Paragraph(tag_txt, S('Tag')) tag_t = Table([[tag_p]], colWidths=[4*cm]) tag_t.setStyle(TableStyle([ ('BACKGROUND',(0,0),(-1,-1),tag_col), ('TOPPADDING',(0,0),(-1,-1),2),('BOTTOMPADDING',(0,0),(-1,-1),2), ('LEFTPADDING',(0,0),(-1,-1),5), ('ROUNDEDCORNERS',(0,0),(-1,-1),[3,3,3,3]), ])) num_p = Paragraph(f'Q{num}.', S('QNum')) hdr_row = Table([[num_p, tag_t]], colWidths=[1.5*cm, 15.5*cm]) hdr_row.setStyle(TableStyle([ ('VALIGN',(0,0),(-1,-1),'MIDDLE'), ('TOPPADDING',(0,0),(-1,-1),0), ('BOTTOMPADDING',(0,0),(-1,-1),0), ])) elems.append(hdr_row) if instruction: elems.append(Paragraph(instruction, S('Inst'))) # Stem stem_rows = [[Paragraph(stem, S('QBody'))]] stem_t = Table(stem_rows, colWidths=[17*cm]) stem_t.setStyle(TableStyle([ ('BACKGROUND',(0,0),(-1,-1), HexColor('#f0f4fb')), ('LEFTPADDING',(0,0),(-1,-1),8), ('RIGHTPADDING',(0,0),(-1,-1),8), ('TOPPADDING',(0,0),(-1,-1),5), ('BOTTOMPADDING',(0,0),(-1,-1),5), ('BOX',(0,0),(-1,-1),0.5,NAVY), ])) elems.append(stem_t) elems.append(Spacer(1,3)) for opt in options: elems.append(Paragraph(opt, S('Option'))) elems.append(HRFlowable(width='100%', thickness=0.3, color=colors.lightgrey, spaceAfter=4, spaceBefore=4)) return elems # ════════════════════════════════════════════════════════════════ # QUESTIONS DATA # ════════════════════════════════════════════════════════════════ questions = [ # Q1 – Decision making STEMI transfer { 'tag': 'STEMI | TIME-CRITICAL DECISION', 'col': RED, 'instruction': 'Clinical vignette – single best answer', 'stem': ( 'A 58-year-old man presents to a community hospital with 2 hours of crushing chest pain, ' 'diaphoresis, and an ECG showing 4 mm ST elevation in leads V1-V4. The nearest PCI-capable ' 'centre is 65 minutes away by ambulance. At the current hospital, thrombolytic therapy can be ' 'administered in 15 minutes. The first medical contact to device time if transferred for primary ' 'PCI is estimated at 110 minutes. What is the MOST appropriate management strategy?' ), 'opts': [ 'a) Administer thrombolytics immediately and plan for elective angiography in 7 days', 'b) Administer thrombolytics immediately followed by immediate facilitated PCI on arrival', 'c) Transfer for primary PCI immediately – estimated door-to-balloon time is within guideline targets', 'd) Administer thrombolytics; transfer for rescue PCI only if clinical/ECG evidence of failed reperfusion', ], 'answer': 'c', }, # Q2 – Cardiogenic shock { 'tag': 'CARDIOGENIC SHOCK | LANDMARK TRIAL', 'col': RED, 'instruction': 'Single best answer', 'stem': ( 'A 72-year-old woman with acute inferior STEMI develops hypotension (BP 80/50 mmHg), pulmonary ' 'oedema, and cool extremities. Her coronary angiogram reveals a 100% occlusion of the RCA. ' 'Which statement BEST reflects current evidence-based management for this presentation?' ), 'opts': [ 'a) Insert an IABP as first line – the IABP-SHOCK II trial demonstrated superior survival with counterpulsation', 'b) Immediate revascularization (PCI or CABG) improves 6- and 12-month survival as demonstrated in the SHOCK trial', 'c) Medical stabilisation with vasopressors is preferred; revascularisation to be deferred 72-96 hours', 'd) Impella CP insertion must precede coronary intervention as it is the only device with proven mortality benefit in cardiogenic shock', ], 'answer': 'b', }, # Q3 – SYNTAX score { 'tag': 'CABG vs PCI | SYNTAX SCORE', 'col': NAVY, 'instruction': 'Operative decision making', 'stem': ( 'A 64-year-old diabetic male is found to have three-vessel coronary artery disease on angiography. ' 'His SYNTAX score is calculated at 36. His left ventricular ejection fraction is 45%. Surgical risk is ' 'moderate. Which revascularisation strategy is supported by current guidelines and Level A evidence?' ), 'opts': [ 'a) PCI with second-generation DES because it has lower stroke rate than CABG', 'b) CABG is preferred; in diabetics multivessel PCI has inferior outcomes regardless of SYNTAX score (FREEDOM trial)', 'c) Either PCI or CABG are equally appropriate as per SYNTAX trial since SYNTAX score <40', 'd) Medical therapy alone should be attempted first for at least 6 months (ISCHEMIA trial)', ], 'answer': 'b', }, # Q4 – LMCA disease { 'tag': 'LEFT MAIN DISEASE | GUIDELINE', 'col': TEAL, 'instruction': 'Guidelines-based question', 'stem': ( 'A 67-year-old man is found to have ostial left main coronary artery stenosis of 65% on angiography ' 'performed for stable angina refractory to medical therapy. His SYNTAX score is 18. His surgical risk ' 'is low. What is the ACC/AHA guideline recommendation for this patient?' ), 'opts': [ 'a) PCI is Class I – superior to CABG for ostial LMCA at any SYNTAX score', 'b) CABG is Class I; PCI with DES is Class IIa as a reasonable alternative given low SYNTAX score and ostial location', 'c) Medical management is preferred as the SYNTAX trial showed no MACE benefit with either procedure', 'd) Balloon aortic valvuloplasty should be performed before revascularisation to assess haemodynamic impact', ], 'answer': 'b', }, # Q5 – Thrombectomy STEMI { 'tag': 'THROMBECTOMY | CLASS III RECOMMENDATION', 'col': RED, 'instruction': 'Guideline/evidence-based decision', 'stem': ( 'A 55-year-old man presents with anterior STEMI and a large thrombus burden in the proximal LAD. ' 'The interventional cardiologist proposes routine manual aspiration thrombectomy prior to stenting. ' 'Which of the following BEST summarises the current evidence and guideline recommendation regarding ' 'routine manual thrombectomy in primary PCI for STEMI?' ), 'opts': [ 'a) Routine thrombectomy is Class I recommended – TAPAS trial showed improved 1-year survival', 'b) Routine thrombectomy is Class IIa – TAPAS showed improved myocardial perfusion without mortality benefit', 'c) Routine manual thrombectomy is Class III (no benefit / potentially harmful) – TOTAL trial showed similar MACE but INCREASED stroke rate', 'd) Mechanical rheolytic thrombectomy (AngioJet) is preferred over manual aspiration for large thrombus burden', ], 'answer': 'c', }, # Q6 – FFR { 'tag': 'INTRAVASCULAR PHYSIOLOGY | FFR', 'col': GREEN, 'instruction': 'Imaging / haemodynamics interpretation', 'stem': ( 'During coronary angiography for stable angina, an intermediate stenosis of 52% is identified in the ' 'mid RCA. The fractional flow reserve (FFR) is measured after intravenous adenosine administration. ' 'The FFR value is 0.83. Which of the following is the MOST appropriate next step?' ), 'opts': [ 'a) Proceed with PCI and stent the lesion as angiographic stenosis >50% is always significant', 'b) Defer revascularisation; FFR ≥0.80 indicates the lesion is not haemodynamically significant', 'c) Repeat FFR after nitroglycerin; adenosine-based FFR is unreliable for intermediate lesions', 'd) Perform IVUS to confirm whether the vessel cross-sectional area is below the threshold for revascularisation', ], 'answer': 'b', }, # Q7 – OCT { 'tag': 'IMAGING | OCT vs IVUS', 'col': GREEN, 'instruction': 'Imaging interpretation and indications', 'stem': ( 'An interventional cardiologist uses optical coherence tomography (OCT) during PCI. The OCT image ' 'reveals a signal-poor region with poorly defined borders adjacent to the vessel wall. ' 'Based on the characteristic OCT morphology described, which plaque type is MOST likely present?' ), 'opts': [ 'a) Fibrous plaque – homogeneous signal-rich region', 'b) Calcific plaque – signal-poor with sharply delineated borders', 'c) Lipid-rich plaque – signal-poor region with poorly defined borders', 'd) White thrombus – mass floating within the lumen with minimal signal attenuation', ], 'answer': 'c', }, # Q8 – IABP { 'tag': 'IABP | MECHANISM & CONTRAINDICATION', 'col': ORANGE, 'instruction': 'Haemodynamics / device selection', 'stem': ( 'A 60-year-old patient is being evaluated for IABP placement in the setting of refractory cardiogenic ' 'shock following anterior MI. Which of the following is an ABSOLUTE contraindication to IABP insertion?' ), 'opts': [ 'a) Thrombocytopenia (platelet count 85,000/µL)', 'b) Severe peripheral vascular disease with bilateral common iliac occlusions', 'c) Anterior STEMI with preserved ejection fraction', 'd) Recent administration of thrombolytics within 12 hours', ], 'answer': 'b', }, # Q9 – Impella RP indications { 'tag': 'MECHANICAL SUPPORT | IMPELLA RP', 'col': RED, 'instruction': 'Device selection and haemodynamics', 'stem': ( 'A 70-year-old man undergoes primary PCI for inferior STEMI complicated by cardiogenic shock. ' 'Despite LV support with Impella CP, he develops progressive right ventricular failure with a CVP ' 'of 22 mmHg, pulmonary artery pressure of 18/8 mmHg, and severely reduced TAPSE on echocardiography. ' 'Which percutaneous device is MOST appropriate for additional right ventricular support?' ), 'opts': [ 'a) TandemHeart in LA-to-femoral artery configuration to reduce RV preload', 'b) Impella RP – aspirates blood from IVC and ejects into pulmonary artery, bypassing the failing RV', 'c) A second Impella CP in the right ventricle', 'd) Transition to ECMO only – percutaneous right ventricular support devices are ineffective for acute RV failure', ], 'answer': 'b', }, # Q10 – DES stent thrombosis { 'tag': 'DES | STENT THROMBOSIS & DAPT', 'col': NAVY, 'instruction': 'Clinical scenario – antiplatelet management', 'stem': ( 'A 55-year-old man received a second-generation DES to a proximal LAD stenosis 8 months ago. He is ' 'now scheduled for an elective total knee replacement. He is currently on aspirin 75 mg and clopidogrel ' '75 mg daily. The orthopaedic surgeon requests discontinuation of clopidogrel 7 days pre-operatively. ' 'Which statement BEST reflects current evidence regarding perioperative antiplatelet management?' ), 'opts': [ 'a) Both aspirin and clopidogrel should be discontinued 7 days before surgery to minimise bleeding', 'b) Aspirin should be continued; clopidogrel discontinuation increases risk of stent thrombosis – surgery should be delayed until 12 months DAPT is complete if possible', 'c) Clopidogrel can be safely stopped as DES-related stent thrombosis only occurs in the first 30 days', 'd) Replace clopidogrel with warfarin bridging therapy before surgery', ], 'answer': 'b', }, # Q11 – BMV { 'tag': 'STRUCTURAL | BALLOON MITRAL VALVULOPLASTY', 'col': TEAL, 'instruction': 'Guidelines – structural intervention', 'stem': ( 'A 38-year-old woman from a rheumatic fever-endemic country presents with severe symptomatic mitral ' 'stenosis (mitral valve area 1.2 cm²). Echocardiography demonstrates pliable, non-calcified leaflets ' 'with minimal subvalvular fusion. Wilkins score is 6. Transesophageal echocardiography excludes left ' 'atrial thrombus. There is trivial mitral regurgitation. What is the MOST appropriate intervention?' ), 'opts': [ 'a) Mitral valve replacement with a mechanical prosthesis', 'b) Open surgical commissurotomy via median sternotomy', 'c) Percutaneous balloon mitral valvuloplasty (PMBV) – treatment of choice given favourable anatomy', 'd) Defer intervention and continue medical management until valve area falls below 1.0 cm²', ], 'answer': 'c', }, # Q12 – HOCM ASA { 'tag': 'STRUCTURAL | ALCOHOL SEPTAL ABLATION', 'col': ORANGE, 'instruction': 'Complication recognition and operative judgement', 'stem': ( 'A 62-year-old man with hypertrophic obstructive cardiomyopathy (HOCM) undergoes alcohol septal ' 'ablation (ASA). Pre-procedure ECG shows a left bundle branch block (LBBB). Four days post-procedure, ' 'he develops syncope. ECG shows complete heart block with a ventricular rate of 32 bpm. ' 'Which statement about this complication is MOST accurate?' ), 'opts': [ 'a) Complete heart block after ASA is extremely rare and was not expected in this patient', 'b) Presence of pre-existing LBBB increases the risk of complete heart block after ASA because ablation targets the basal septum near the right bundle', 'c) This complication is unique to alcohol septal ablation and does not occur after surgical myectomy', 'd) The patient should be given atropine and isoprenaline as the block is transient in >90% of cases', ], 'answer': 'b', }, # Q13 – PFO closure trial knowledge { 'tag': 'STRUCTURAL | PFO CLOSURE TRIALS', 'col': TEAL, 'instruction': 'Landmark trial knowledge', 'stem': ( 'A 44-year-old man with a history of two cryptogenic strokes on antiplatelet therapy is found to ' 'have a large patent foramen ovale with an associated atrial septal aneurysm on transesophageal ' 'echocardiography. Which of the following BEST reflects the current evidence for PFO closure in ' 'this clinical scenario?' ), 'opts': [ 'a) Pooled analysis of CLOSURE I, PC, and RESPECT showed statistically significant reduction in recurrent stroke – percutaneous closure is Class I', 'b) The CLOSURE I device remains the gold standard for PFO closure based on the largest RCT', 'c) The Amplatzer PFO Occluder is FDA-approved; RESPECT extended + REDUCE + CLOSE trials demonstrate clear reduction in stroke risk – this patient is high-benefit (large shunt + septal aneurysm)', 'd) Anticoagulation with warfarin is equivalent to device closure and should be preferred in all patients', ], 'answer': 'c', }, # Q14 – MitraClip { 'tag': 'STRUCTURAL | MitraClip COAPT', 'col': TEAL, 'instruction': 'Clinical scenario – structural decision making', 'stem': ( 'A 68-year-old man with ischaemic cardiomyopathy (LVEF 28%) and NYHA class III symptoms has ' 'severe secondary (functional) mitral regurgitation (MR grade 4+). He is on optimised guideline-directed ' 'medical therapy including an ACE inhibitor, beta-blocker, and CRT-D. He has been assessed by the ' 'heart team and found to be at prohibitive surgical risk. Which intervention has demonstrated both ' 'reduced heart failure hospitalisations AND reduced mortality in this specific scenario?' ), 'opts': [ 'a) Surgical mitral valve replacement via minimally invasive approach', 'b) Percutaneous MitraClip implantation – supported by the COAPT trial demonstrating reduced HF hospitalisation and mortality', 'c) Transcatheter aortic valve replacement (TAVR) to reduce afterload', 'd) Intra-aortic balloon pump as a long-term circulatory support strategy', ], 'answer': 'b', }, # Q15 – SVG PCI { 'tag': 'CATHETER-BASED THERAPY | SVG PCI', 'col': NAVY, 'instruction': 'Post-CABG scenario – operative judgement', 'stem': ( 'A 72-year-old male who had CABG 11 years ago presents with recurrent angina. Angiography reveals ' 'a degenerated saphenous vein graft (SVG) to the RCA with a 75% stenosis and thrombus-containing ' 'lesion. The native RCA is chronically occluded. What is the MOST appropriate adjunctive device ' 'strategy during PCI of this SVG lesion?' ), 'opts': [ 'a) Rotational atherectomy to debulk the degenerated SVG plaque before stenting', 'b) Use of a distal embolic protection device – supported by SAFER trial (50% reduction in periprocedural MI)', 'c) Routine aspiration thrombectomy – Class I recommendation for SVG PCI with thrombus', 'd) Manual balloon dilation without stenting to minimise thromboembolism risk', ], 'answer': 'b', }, # Q16 – Contrast nephropathy prevention { 'tag': 'COMPLICATIONS | CONTRAST-INDUCED NEPHROPATHY', 'col': ORANGE, 'instruction': 'Complication prevention', 'stem': ( 'A 65-year-old patient with CKD (eGFR 32 mL/min/1.73m²) is scheduled for elective coronary ' 'angiography with likely PCI. He has a creatinine of 2.4 mg/dL. Which strategy has the STRONGEST ' 'evidence for preventing contrast-induced nephropathy (CIN)?' ), 'opts': [ 'a) High-dose N-acetylcysteine (NAC) orally for 24 hours before and after the procedure', 'b) Pre-hydration and post-hydration with isotonic normal saline', 'c) Fenoldopam infusion during the procedure to promote renal vasodilation', 'd) Forced diuresis with furosemide + mannitol infusion during contrast administration', ], 'answer': 'b', }, # Q17 – Restenosis mechanism { 'tag': 'RESTENOSIS | MECHANISM & DES', 'col': GREEN, 'instruction': 'Pathophysiology and technology', 'stem': ( 'A 58-year-old man presents 6 months after BMS placement to the LAD with recurrent angina. ' 'Repeat angiography confirms in-stent restenosis with 75% stenosis. Which of the following ' 'BEST describes the primary mechanism of in-stent restenosis and the action of drug-eluting stents?' ), 'opts': [ 'a) Stent fracture leading to thrombosis; DES prevents stent fracture through polymer flexibility', 'b) Smooth muscle cell proliferation and neointimal hyperplasia; DES elutes anti-proliferative drugs (e.g., sirolimus, paclitaxel) that inhibit the cell cycle', 'c) Macrophage-mediated plaque rupture; DES stabilises plaque with anti-inflammatory coating', 'd) Elastic recoil of the arterial wall; DES stent design prevents radial collapse', ], 'answer': 'b', }, # Q18 – CIN risk score { 'tag': 'CIN | RISK PREDICTION', 'col': ORANGE, 'instruction': 'Risk stratification', 'stem': ( 'According to the Mehran risk score for contrast-induced nephropathy (CIN) after PCI, which ' 'combination of factors places a patient at HIGHEST risk for developing CIN?' ), 'opts': [ 'a) Male sex, age 45, normal renal function, elective PCI with 80 mL of contrast', 'b) Hypotension requiring IABP support, CHF, CKD (eGFR 28), diabetes mellitus, age 78, anaemia, large contrast volume', 'c) Hypertension, hyperlipidaemia, smoking, stable angina, preserved renal function', 'd) Female sex, age 55, mild obesity, normal creatinine, 100 mL contrast volume', ], 'answer': 'b', }, # Q19 – ASD closure candidates { 'tag': 'STRUCTURAL | ASD – PATIENT SELECTION', 'col': TEAL, 'instruction': 'Patient selection for percutaneous vs surgical closure', 'stem': ( 'A 35-year-old woman with a secundum atrial septal defect (ASD) is referred for closure. ' 'Transoesophageal echocardiography reveals a 22 mm defect with 6 mm of surrounding tissue on all ' 'rims, a Qp:Qs of 1.8, and mild right ventricular dilatation. There is no pulmonary hypertension. ' 'Which closure strategy is MOST appropriate?' ), 'opts': [ 'a) Surgical closure is mandatory as percutaneous ASD closure is only appropriate for defects <10 mm', 'b) Percutaneous transcatheter device closure is appropriate – suitable anatomy, Qp:Qs ≥1.5, and RV dilatation justify closure', 'c) Medical management with pulmonary vasodilators is preferred to avoid stroke risk of closure procedures', 'd) Closure is not indicated as this patient is asymptomatic; intervention reserved for symptomatic patients only', ], 'answer': 'b', }, # Q20 – PCI before noncardiac surgery { 'tag': 'PERIOPERATIVE | PCI + NON-CARDIAC SURGERY', 'col': NAVY, 'instruction': 'Perioperative decision making', 'stem': ( 'A 61-year-old man with stable angina had a second-generation DES placed to the proximal LAD ' '4 weeks ago. He is now presenting for elective repair of an inguinal hernia. He stopped clopidogrel ' '5 days ago due to concerns about intraoperative bleeding. On examination, he is haemodynamically ' 'stable. Which of the following statements is MOST accurate regarding his perioperative management?' ), 'opts': [ 'a) Surgery is safe to proceed; DES-related thrombosis risk is highest at implant and negligible by 4 weeks', 'b) Surgery should be deferred; surgery within 6 weeks of stent placement is associated with higher adverse events including death and MI – premature DAPT discontinuation amplifies stent thrombosis risk', 'c) He should receive prophylactic IABP during the surgery to prevent periprocedural ischaemia', 'd) Bridging anticoagulation with IV heparin will adequately protect against stent thrombosis in the perioperative period', ], 'answer': 'b', }, ] # ════════════════════════════════════════════════════════════════ # BUILD PDF2 # ════════════════════════════════════════════════════════════════ doc2 = SimpleDocTemplate( '/home/daytona/workspace/ini_ss_ch56/PDF2_MCQ_Questions.pdf', pagesize=A4, leftMargin=1.8*cm, rightMargin=1.8*cm, topMargin=1.8*cm, bottomMargin=1.8*cm ) story2 = [] # Cover cov = Table([[ Paragraph('INI SS CET – CARDIOTHORACIC & VASCULAR SURGERY', S('SubT')), Paragraph('CHAPTER 56: INTERVENTIONAL CARDIOLOGY', S('Title')), Paragraph('Question Paper | 20 Single Best Answer MCQs | Time: 40 minutes', S('SubT')), ]], colWidths=[17*cm]) cov.setStyle(TableStyle([ ('BACKGROUND',(0,0),(-1,-1),NAVY), ('TOPPADDING',(0,0),(-1,-1),12),('BOTTOMPADDING',(0,0),(-1,-1),12), ('LEFTPADDING',(0,0),(-1,-1),8), ('SPAN',(0,0),(-1,-1)), ])) story2.append(cov) story2.append(Spacer(1,6)) # Instructions box inst_items = [ '• Each question has ONE single best answer from options a, b, c, d.', '• There is NO negative marking.', '• Questions cover: clinical decision making, landmark trials, operative judgement, haemodynamics, guidelines, and imaging interpretation.', '• Answer key with detailed explanations is provided in a separate PDF.', ] inst_data = [[Paragraph('INSTRUCTIONS', ParagraphStyle('iT', fontName='Helvetica-Bold', fontSize=10, textColor=white))]] t_inst = Table(inst_data, colWidths=[17*cm]) t_inst.setStyle(TableStyle([ ('BACKGROUND',(0,0),(-1,-1),TEAL), ('TOPPADDING',(0,0),(-1,-1),4),('BOTTOMPADDING',(0,0),(-1,-1),4), ('LEFTPADDING',(0,0),(-1,-1),8), ])) story2.append(t_inst) for i in inst_items: story2.append(Paragraph(i, S('Body'))) story2.append(Spacer(1,6)) for idx, q in enumerate(questions, 1): qblk = q_box(idx, q['tag'], q['col'], q['stem'], q['opts'], q.get('instruction','')) for e in qblk: story2.append(e) doc2.build(story2) print('PDF2 done') PYEOF echo "Exit: $?"

ls -lh /home/daytona/workspace/ini_ss_ch56/ 2>/dev/null && echo "---" && ls /home/daytona/workspace/chapter56_full.txt 2>/dev/null && echo "Chapter text: OK"

python3 << 'PYEOF' from reportlab.lib.pagesizes import A4 from reportlab.lib.styles import ParagraphStyle from reportlab.lib.units import cm from reportlab.lib.colors import HexColor, black, white from reportlab.platypus import (SimpleDocTemplate, Paragraph, Spacer, Table, TableStyle, PageBreak, HRFlowable, KeepTogether) from reportlab.lib.enums import TA_CENTER, TA_LEFT, TA_JUSTIFY import reportlab.lib.colors as colors NAVY = HexColor('#1a3a5c') TEAL = HexColor('#0a7c7c') ORANGE = HexColor('#e07b00') RED = HexColor('#c0392b') GREEN = HexColor('#1a7a44') LTBLUE = HexColor('#dbeeff') LTGREEN = HexColor('#d4edda') LTRED = HexColor('#fde8e8') LTYELLOW= HexColor('#fff9e0') SILVER = HexColor('#f4f6f8') GOLD = HexColor('#f5c842') def SP(name): d = { 'Title': ParagraphStyle('Title', fontName='Helvetica-Bold', fontSize=18, textColor=white, alignment=TA_CENTER, leading=22), 'Sub': ParagraphStyle('Sub', fontName='Helvetica', fontSize=10, textColor=LTBLUE, alignment=TA_CENTER), 'QHdr': ParagraphStyle('QHdr', fontName='Helvetica-Bold', fontSize=12, textColor=white, leading=15), 'Correct':ParagraphStyle('Correct',fontName='Helvetica-Bold', fontSize=11, textColor=GREEN, leading=14, spaceBefore=2, spaceAfter=2), 'Body': ParagraphStyle('Body', fontName='Helvetica', fontSize=9.5,textColor=black, leading=14, spaceAfter=3, alignment=TA_JUSTIFY), 'Bold': ParagraphStyle('Bold', fontName='Helvetica-Bold', fontSize=9.5,textColor=black, leading=14, spaceAfter=2), 'Label': ParagraphStyle('Label', fontName='Helvetica-Bold', fontSize=9, textColor=white, leading=12), 'Dist': ParagraphStyle('Dist', fontName='Helvetica-Bold', fontSize=9.5,textColor=RED, leading=14, spaceAfter=1), 'DistB': ParagraphStyle('DistB', fontName='Helvetica', fontSize=9, textColor=black, leading=13, spaceAfter=3, leftIndent=8, alignment=TA_JUSTIFY), 'GL': ParagraphStyle('GL', fontName='Helvetica-Bold', fontSize=9, textColor=ORANGE, leading=13, spaceAfter=2), 'LP': ParagraphStyle('LP', fontName='Helvetica-Bold', fontSize=9, textColor=GREEN, leading=13, spaceAfter=2), 'Small': ParagraphStyle('Small', fontName='Helvetica', fontSize=8.5,textColor=black, leading=12), } return d[name] def badge(text, bg): p = Paragraph(text, SP('Label')) t = Table([[p]], colWidths=[4*cm]) t.setStyle(TableStyle([ ('BACKGROUND',(0,0),(-1,-1),bg), ('TOPPADDING',(0,0),(-1,-1),2),('BOTTOMPADDING',(0,0),(-1,-1),2), ('LEFTPADDING',(0,0),(-1,-1),6), ])) return t def colored_label_box(label, text, label_bg, body_bg): lp = Paragraph(label, SP('Label')) lt = Table([[lp]], colWidths=[4*cm]) lt.setStyle(TableStyle([('BACKGROUND',(0,0),(-1,-1),label_bg), ('TOPPADDING',(0,0),(-1,-1),2),('BOTTOMPADDING',(0,0),(-1,-1),2), ('LEFTPADDING',(0,0),(-1,-1),6)])) bp = Paragraph(text, SP('Body')) bt = Table([[bp]], colWidths=[17*cm]) bt.setStyle(TableStyle([('BACKGROUND',(0,0),(-1,-1),body_bg), ('TOPPADDING',(0,0),(-1,-1),4),('BOTTOMPADDING',(0,0),(-1,-1),4), ('LEFTPADDING',(0,0),(-1,-1),8), ('RIGHTPADDING',(0,0),(-1,-1),8), ('BOX',(0,0),(-1,-1),0.3,colors.grey)])) return [lt, bt, Spacer(1,2)] # ════════════════════════════════════════════════════════════════ # ANSWER DATA – all 20 detailed explanations # ════════════════════════════════════════════════════════════════ answers = [ { 'qnum': 1, 'tag': 'STEMI | TIME-CRITICAL DECISION', 'tag_col': RED, 'correct_opt': 'c', 'correct_text': 'c) Transfer for primary PCI immediately – estimated door-to-balloon time is within guideline targets', 'explanation': ( 'Current ACC/AHA and ESC guidelines state that primary PCI is the preferred reperfusion strategy ' 'for STEMI when it can be performed within 90 minutes of first medical contact (≤120 minutes if ' 'transfer is required). In this case, the estimated FMC-to-device time is 110 minutes, which is ' 'within the 120-minute transfer threshold. Primary PCI has been shown to be superior to ' 'thrombolytic therapy in large-vessel patency rates (>90%), reduced reinfarction, reduced mortality, ' 'and lower rates of haemorrhagic stroke when time targets are met. Transfer for primary PCI is ' 'therefore the correct choice.' ), 'distractors': [ ('a) Administer thrombolytics + elective angiography in 7 days', 'This is incorrect. Elective angiography at 7 days would only be appropriate for clinically stable ' 'patients with successful thrombolysis (pharmacoinvasive strategy). Here, primary PCI is achievable ' 'within guideline time targets and should not be replaced by an inferior strategy.'), ('b) Thrombolytics + immediate facilitated PCI', 'Facilitated PCI – the strategy of giving thrombolytics with the intent to improve PCI outcomes ' 'through concurrent fibrinolysis – is specifically contraindicated. Additional fibrinolytic therapy ' 'at the time of immediate PCI is associated with ADVERSE consequences per ACC/AHA guidelines. ' 'This must be distinguished from the pharmacoinvasive strategy (fibrinolysis when PCI is delayed, ' 'then PCI 3–24 h later).'), ('d) Thrombolytics + rescue PCI only if failed', 'The pharmacoinvasive strategy (thrombolytics + planned rescue/routine PCI) is appropriate ONLY ' 'when PCI cannot be performed within guideline time limits. Here, transfer PCI is achievable within ' '120 minutes, so this option is suboptimal and exposes the patient to the added risk of thrombolytics.'), ], 'guideline': 'ACC/AHA 2013 STEMI Guideline: FMC-to-device ≤90 min; ≤120 min if transfer required (Class I, Level A). Facilitated PCI is NOT recommended (Class III).', 'learning': 'When transfer-PCI time is within 120 minutes, primary PCI is always preferred. Facilitated PCI is harmful – never combine thrombolytics with the intent of immediate PCI.', }, { 'qnum': 2, 'tag': 'CARDIOGENIC SHOCK | LANDMARK TRIAL', 'tag_col': RED, 'correct_opt': 'b', 'correct_text': 'b) Immediate revascularization (PCI or CABG) improves 6- and 12-month survival – SHOCK trial', 'explanation': ( 'The SHOCK trial (Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock) ' 'remains the landmark RCT demonstrating that immediate revascularization – using either PCI or ' 'CABG – significantly improves survival at both 6 months and 12 months compared with initial ' 'medical stabilisation (fibrinolysis, delayed revascularisation, or both). A GUSTO-I subset ' 'analysis confirmed similar long-term benefit. Therefore, immediate revascularisation is ' 'the standard of care for cardiogenic shock complicating acute MI.' ), 'distractors': [ ('a) IABP as first line – IABP-SHOCK II trial proved superior survival', 'This is factually incorrect. The IABP-SHOCK II trial (N=600; Lancet 2013) specifically showed ' 'that IABP use in cardiogenic shock complicating MI with PCI had NO survival advantage (39.7% vs ' '41.3%; relative risk 0.96). Routine IABP use in cardiogenic shock is NO LONGER RECOMMENDED.'), ('c) Medical stabilisation; revascularisation deferred 72-96 hours', 'This was the comparator arm in the SHOCK trial and was shown to be INFERIOR. Deferred revascularisation ' 'results in significantly worse survival at 6 and 12 months. Every hour of delay worsens myocardial ' 'salvage and end-organ perfusion.'), ('d) Impella CP must precede coronary intervention – only device with proven mortality benefit', 'While Impella devices are approved for cardiogenic shock and may provide haemodynamic support, ' 'observational data have NOT shown a clear mortality advantage for Impella in cardiogenic shock ' 'complicating MI. Furthermore, delay to coronary intervention to insert a device is counterproductive. ' 'The SHOCK trial evidence applies to PCI and CABG, not to a specific mechanical support device.'), ], 'guideline': 'SHOCK Trial (JAMA 1999/Circulation 1999): Immediate revascularization superior to medical stabilisation for cardiogenic shock. IABP-SHOCK II (Lancet 2013): IABP has NO survival benefit in cardiogenic shock – routine use not recommended.', 'learning': 'The SHOCK trial supports immediate revascularisation (PCI or CABG) in cardiogenic shock. IABP-SHOCK II de-escalated routine IABP use. The EXCEPTION in SHOCK trial: patients >75 years had reduced survival with immediate revascularisation.', }, { 'qnum': 3, 'tag': 'CABG vs PCI | SYNTAX SCORE + DIABETES', 'tag_col': NAVY, 'correct_opt': 'b', 'correct_text': 'b) CABG preferred; in diabetics with multivessel disease PCI is inferior regardless of SYNTAX score (FREEDOM trial)', 'explanation': ( 'The FREEDOM trial (N=1900, NEJM 2012) is the definitive RCT for diabetic patients with multivessel ' 'disease. It demonstrated that CABG is significantly superior to PCI with DES, with 5-year composite ' 'MACE of 18.7% (CABG) vs 26.6% (PCI), driven by lower rates of death (10.9% vs 16.3%) and MI ' '(6.0% vs 13.9%). Crucially, this benefit was present regardless of SYNTAX score – including low, ' 'intermediate, and high scores. SYNTAX score 36 is in the HIGH category (≥33), which independently ' 'favours CABG in non-diabetics as well. The SYNTAX trial confirmed CABG superiority over paclitaxel ' 'DES in intermediate-to-high SYNTAX scores for 3-vessel/LMCA disease.' ), 'distractors': [ ('a) PCI with DES because it has lower stroke rate', 'While it is true that CABG carries a higher stroke rate than PCI (SYNTAX: CABG 3.7% vs PCI 2.6% ' 'stroke at 5 yrs; FREEDOM: CABG 5.2% vs PCI 2.4%), this single advantage does not outweigh the ' 'significantly higher rates of death and MI with PCI in diabetics with multivessel disease. ' 'Stroke risk alone does not determine revascularisation choice in this scenario.'), ('c) Either equally appropriate as SYNTAX <40', 'This is incorrect. There is no "SYNTAX <40" threshold. The SYNTAX score categories are: low (0-22), ' 'intermediate (23-32), and high (≥33). A score of 36 is HIGH, which strongly favours CABG. ' 'Furthermore, in FREEDOM, the SYNTAX score did not modify the CABG advantage in diabetics.'), ('d) Medical therapy alone for 6 months first (ISCHEMIA trial)', 'The ISCHEMIA trial applied to patients with stable CAD and moderate-to-severe ischemia without ' 'cardiogenic shock or LMCA disease. It does not apply to diabetic patients with three-vessel disease ' 'and high SYNTAX scores, where revascularisation is clearly indicated and CABG is preferred.'), ], 'guideline': 'FREEDOM Trial (NEJM 2012): CABG superior to DES in diabetics with multivessel disease regardless of SYNTAX score. SYNTAX Trial (NEJM 2009; Lancet 2013): CABG superior for 3-vessel/LM disease with intermediate/high SYNTAX score.', 'learning': 'FREEDOM trial = diabetes + multivessel → CABG always preferred. SYNTAX score ≥33 → CABG preferred. Low SYNTAX (0-22) → PCI and CABG have similar outcomes.', }, { 'qnum': 4, 'tag': 'LEFT MAIN DISEASE | GUIDELINE', 'tag_col': TEAL, 'correct_opt': 'b', 'correct_text': 'b) CABG is Class I; PCI with DES is Class IIa (reasonable alternative) given low SYNTAX score and ostial location', 'explanation': ( 'According to ACC/AHA 2011 PCI guidelines, CABG is Class I (strongly recommended) for patients with ' 'significant LMCA stenosis (≥50%). However, PCI is classified as Class IIa (reasonable alternative) ' 'for select patients with coronary anatomy predictive of low PCI complication risk and good outcomes, ' 'including SYNTAX score ≤22 or ostial LMCA disease, as well as patients with increased surgical risk. ' 'The EXCEL trial (NEJM 2019) confirmed no significant difference in the composite endpoint of death, ' 'stroke, or MI at 5 years between PCI and CABG for LMCA disease of low-to-intermediate SYNTAX score ' '(15.4% PCI vs 14.7% CABG). This patient has SYNTAX 18 (low) and ostial LMCA, supporting PCI as a ' 'Class IIa alternative, but CABG remains the Class I recommendation.' ), 'distractors': [ ('a) PCI is Class I – superior to CABG for ostial LMCA at any SYNTAX score', 'This is incorrect. PCI for LMCA disease is Class IIa, not Class I. CABG remains the Class I ' 'recommendation. EXCEL trial showed similar (not superior) outcomes for PCI compared to CABG. ' 'There is no "any SYNTAX score" provision that makes PCI Class I.'), ('c) Medical management preferred as SYNTAX showed no MACE benefit', 'The SYNTAX trial did NOT show equivalence of medical management. It compared PCI vs CABG for ' 'revascularisation. The ISCHEMIA trial excluded LMCA disease >50% from its medical management arm. ' 'Medical management alone is NOT appropriate for significant LMCA stenosis with ischaemic symptoms.'), ('d) Balloon aortic valvuloplasty to assess haemodynamic impact', 'BAV is used to assess haemodynamic impact in low-output, low-gradient AORTIC STENOSIS – it has ' 'no role in assessing the significance of LMCA coronary disease. FFR or IVUS are the appropriate ' 'tools for intermediate coronary stenosis assessment.'), ], 'guideline': 'ACC/AHA 2011 PCI Guidelines: CABG = Class I for LMCA ≥50%. PCI = Class IIa for SYNTAX ≤22, ostial LMCA, or high surgical risk. ACCF/SCAI/STS 2012 Appropriate Use Criteria: PCI for LMCA with low SYNTAX = "uncertain"; CABG = "appropriate".', 'learning': 'LMCA disease: CABG = Class I always. PCI = Class IIa when SYNTAX ≤22, ostial location, or prohibitive surgical risk. EXCEL trial: PCI and CABG have similar 5-year outcomes for low-to-intermediate SYNTAX LMCA disease.', }, { 'qnum': 5, 'tag': 'THROMBECTOMY | CLASS III RECOMMENDATION', 'tag_col': RED, 'correct_opt': 'c', 'correct_text': 'c) Routine manual thrombectomy is Class III (no benefit / potentially harmful) – TOTAL trial: similar MACE + increased stroke', 'explanation': ( 'The TOTAL trial (NEJM 2015; N=10,732) is the largest RCT of manual thrombectomy during primary PCI ' 'for STEMI. It showed SIMILAR rates of cardiovascular death, recurrent MI, cardiogenic shock, and ' 'class IV heart failure at 180 days (6.9% thrombectomy vs 7.0% PCI alone; P=0.86). However, there ' 'was a SIGNIFICANT INCREASE in stroke at 30 days with thrombectomy (0.7% vs 0.3%; P=0.02). ' 'One-year follow-up confirmed similar findings. This downgraded routine aspiration thrombectomy ' 'from Class IIa to Class III (not useful, potentially harmful) in current guidelines. ' 'The earlier TASTE trial also showed no mortality benefit. Aspiration thrombectomy may still be ' 'reserved (as a bailout) for selected cases with very high thrombus burden and large myocardium at risk.' ), 'distractors': [ ('a) Class I – TAPAS trial showed improved 1-year survival', 'TAPAS (NEJM 2008; N=1071) demonstrated improved myocardial perfusion (ST-resolution, blush grade) ' 'and 1-year cardiac death/reinfarction benefit. However, TAPAS was a single-centre trial with ' 'important limitations. The larger TASTE (N=7244) and TOTAL (N=10,732) trials did NOT confirm this ' 'survival benefit, leading to downgrading. Evidence always follows the largest, most rigorous trials.'), ('b) Class IIa – TAPAS showed perfusion benefit without mortality benefit', 'While historically thrombectomy was IIa based on TAPAS, the TOTAL trial\'s stroke finding actively ' 'HARMED patients. Current guidelines classify routine aspiration thrombectomy as Class III – it is ' 'no longer recommended routinely. This is a frequently tested reversal in cardiology guidelines.'), ('d) Mechanical rheolytic thrombectomy (AngioJet) preferred for large thrombus', 'This is INCORRECT and potentially dangerous. The AiMI trial (N=480) specifically showed that ' 'AngioJet rheolytic mechanical thrombectomy in STEMI resulted in LARGER infarct size (technetium ' 'sestamibi) and HIGHER mortality compared with conventional primary angioplasty. Mechanical ' 'thrombectomy in STEMI is considered harmful.'), ], 'guideline': 'TOTAL Trial (NEJM 2015): Routine manual thrombectomy → Class III. AiMI Trial: Mechanical (AngioJet) thrombectomy → harmful in STEMI. SAFER trial: Distal embolic protection in SVG PCI = Class IIa (50% reduction in periprocedural MI).', 'learning': 'Thrombectomy guideline evolution: TAPAS (IIa) → TASTE + TOTAL (Class III). TOTAL trial uniquely showed INCREASED STROKE. Aspiration thrombectomy is reserved as bailout, not routine. AngioJet in STEMI = harmful (AiMI trial).', }, { 'qnum': 6, 'tag': 'INTRAVASCULAR PHYSIOLOGY | FFR', 'tag_col': GREEN, 'correct_opt': 'b', 'correct_text': 'b) Defer revascularisation; FFR ≥0.80 indicates the lesion is not haemodynamically significant', 'explanation': ( 'Fractional flow reserve (FFR) is an invasive physiologic measurement that compares distal coronary ' 'pressure to proximal aortic pressure during maximal hyperemia (induced by intravenous adenosine). ' 'An FFR value of 0.83 is ABOVE the established cut-off of 0.80. Values ≥0.80 indicate the stenosis ' 'is NOT haemodynamically significant, and revascularisation can be safely deferred. The DEFER trial ' 'established that lesions with FFR ≥0.75 had excellent prognosis without revascularisation; ' 'subsequent FAME and FAME-2 trials confirmed 0.80 as the standard cut-off. FFR is particularly ' 'valuable for intermediate stenoses (40-70% by angiography) and is superior to IVUS for determining ' 'haemodynamic significance outside of LMCA disease.' ), 'distractors': [ ('a) Proceed with PCI as angiographic stenosis >50% is always significant', 'Angiographic visual estimation is notoriously unreliable for intermediate stenoses (40-70%). ' 'Multiple studies have shown that angiographically "significant" lesions are frequently not ' 'haemodynamically significant by FFR. Physiologic assessment with FFR is precisely designed to ' 'avoid unnecessary stenting of non-flow-limiting stenoses.'), ('c) Repeat FFR after nitroglycerin; adenosine-based FFR is unreliable for intermediate lesions', 'This is incorrect. Adenosine-induced maximal hyperaemia is the validated standard for FFR ' 'measurement. Nitroglycerin does not induce maximal hyperaemia for FFR assessment. Resting ' 'indices (iFR, RFR, dPR) are validated alternatives to hyperaemic FFR, not nitroglycerin-based ' 'assessment. The statement implies a reliability problem with FFR that does not exist.'), ('d) Perform IVUS to confirm cross-sectional area', 'While IVUS can assess plaque and vessel dimensions, it is an anatomical tool and does NOT ' 'directly measure haemodynamic significance. FFR is acknowledged as SUPERIOR to IVUS for ' 'determining whether an intermediate stenosis warrants revascularisation (outside LMCA). ' 'When FFR already provides a definitive answer (0.83 = defer), IVUS adds no additional value.'), ], 'guideline': 'DEFER/FAME/FAME-2 Trials: FFR ≥0.80 = defer revascularisation safely. ACC/AHA guidelines: FFR is preferred physiologic assessment for intermediate stenoses (Class I, Level A for FFR guidance of PCI).', 'learning': 'FFR cut-off: <0.80 = haemodynamically significant → revascularise. ≥0.80 = defer. FFR is superior to IVUS outside LMCA for functional significance. Resting indices (iFR, RFR) are now equivalent alternatives to hyperaemic FFR.', }, { 'qnum': 7, 'tag': 'IMAGING | OCT MORPHOLOGY', 'tag_col': GREEN, 'correct_opt': 'c', 'correct_text': 'c) Lipid-rich plaque – signal-poor region with POORLY DEFINED borders', 'explanation': ( 'Optical coherence tomography (OCT) uses near-infrared light to provide 10-fold higher spatial ' 'resolution than IVUS. The question describes a signal-poor region with POORLY DEFINED borders – ' 'this is the classic OCT appearance of lipid-rich plaque, because lipid causes light attenuation ' 'with diffuse, indistinct margins. Importantly, the media may not be visible beyond lipid-rich ' 'areas due to signal attenuation. Each plaque type has a distinct OCT signature:\n' '• Normal artery: 3-layered bright-dark-bright (intima-media-adventitia)\n' '• Fibrous plaque: homogeneous, signal-RICH (bright)\n' '• Calcific plaque: signal-POOR with SHARPLY delineated borders (like a window)\n' '• Lipid-rich plaque: signal-POOR with POORLY defined (fuzzy) borders\n' '• White thrombus: floating mass with MINIMAL signal attenuation (platelet/WBC rich)\n' '• Red thrombus: floating/attached mass with HIGH attenuation, casting a shadow (RBC rich)' ), 'distractors': [ ('a) Fibrous plaque – homogeneous signal-rich', 'Fibrous plaque on OCT is homogeneous and SIGNAL-RICH (bright), NOT signal-poor. The stem ' 'explicitly states "signal-poor region" which excludes fibrous plaque.'), ('b) Calcific plaque – signal-poor with sharply delineated borders', 'Calcific plaque is indeed signal-poor BUT has SHARPLY delineated (well-defined) borders with ' 'clear angular margins. The stem describes POORLY DEFINED borders, which is the key distinction ' 'that differentiates lipid-rich from calcific plaque on OCT.'), ('d) White thrombus – floating mass with minimal attenuation', 'White (platelet-rich) thrombus appears as a MASS FLOATING within the lumen with MINIMAL OCT ' 'signal attenuation (not signal-poor in the plaque wall). Red thrombus casts a shadow due to high ' 'RBC-mediated attenuation. Neither matches the fixed wall plaque description in the stem.'), ], 'guideline': 'Ali ZA et al. JACC Cardiovasc Intv 2017: OCT 2018 – current status and future directions. OCT provides 10-fold higher resolution than IVUS; gold standard for plaque characterisation and stent assessment.', 'learning': 'OCT plaque types: Fibrous = bright/rich; Calcific = dark with sharp borders; Lipid = dark with fuzzy borders; White thrombus = floating, minimal attenuation; Red thrombus = floating, high attenuation with shadow. Calcific vs lipid: both are signal-poor; border definition is the differentiator.', }, { 'qnum': 8, 'tag': 'IABP | MECHANISM & CONTRAINDICATION', 'tag_col': ORANGE, 'correct_opt': 'b', 'correct_text': 'b) Severe peripheral vascular disease with bilateral common iliac occlusions', 'explanation': ( 'The intra-aortic balloon pump (IABP) is placed via the common femoral artery (or occasionally ' 'axillary/iliac approach). Severe peripheral vascular disease (PVD) with bilateral common iliac ' 'occlusions is a well-recognised absolute contraindication because it makes femoral access ' 'impossible and the balloon cannot be safely positioned. Other absolute contraindications to IABP ' 'include: moderate-to-severe aortic regurgitation (counterpulsation worsens AR), aortic dissection, ' 'and severe aortic atherosclerosis. The mechanism of IABP is counterpulsation: the balloon inflates ' 'in early diastole (increases diastolic coronary perfusion pressure) and deflates at end-diastole/' 'early systole (reduces ventricular afterload), improving myocardial oxygen supply/demand balance.' ), 'distractors': [ ('a) Thrombocytopenia (platelet count 85,000/µL)', 'Mild-to-moderate thrombocytopenia is a RELATIVE (not absolute) contraindication to IABP. ' 'The device can still be placed with thrombocytopenia if the clinical benefit outweighs the ' 'bleeding risk, with careful monitoring. A platelet count of 85,000/µL is not an absolute ' 'barrier in a haemodynamically unstable patient.'), ('c) Anterior STEMI with preserved EF', 'STEMI with preserved ejection fraction and no cardiogenic shock is not a contraindication to ' 'IABP – in fact, IABP has historically been used as adjunctive support in high-risk PCI. ' 'However, the CRISP-AMI trial showed no reduction in infarct size with routine IABP in anterior ' 'MI without shock, so routine use is not indicated – but it is not contraindicated.'), ('d) Thrombolytics within 12 hours', 'Recent thrombolytic therapy is not listed as a contraindication to IABP placement. Vascular ' 'access complications may be increased in anticoagulated/thrombolysed patients, making this a ' 'relative concern, but not an absolute contraindication. The primary contraindications are ' 'anatomical (aortic regurgitation, dissection, severe PVD, severe atherosclerosis).'), ], 'guideline': 'ACC/AHA/SCAI PCI Guidelines: IABP contraindicated in: aortic regurgitation (moderate/severe), aortic dissection, significant peripheral vascular disease. IABP-SHOCK II: No survival benefit in cardiogenic shock with routine use.', 'learning': 'IABP contraindications: aortic regurgitation (worsens regurgitant volume), aortic dissection (risk of propagation), severe PVD (access impossible). IABP mechanism: diastolic augmentation (↑coronary flow) + systolic unloading (↓afterload).', }, { 'qnum': 9, 'tag': 'MECHANICAL SUPPORT | IMPELLA RP', 'tag_col': RED, 'correct_opt': 'b', 'correct_text': 'b) Impella RP – aspirates blood from IVC and ejects into pulmonary artery, bypassing the failing RV', 'explanation': ( 'The Impella RP is a catheter-mounted microaxial blood pump inserted via the femoral vein and ' 'positioned so that the pump inflow is in the inferior vena cava (IVC) and the pump outflow is in ' 'the pulmonary artery (PA). This configuration bypasses a failing right ventricle by aspirating blood ' 'from the IVC and ejecting it into the PA, providing up to 5 L/min of flow. It is approved for ' 'acute right heart failure, RV decompensation following LVAD placement, acute MI, and cardiac surgery. ' 'The RECOVER RIGHT prospective cohort demonstrated haemodynamic effectiveness. The patient here has ' 'elevated CVP, low PA pressures consistent with poor RV output, and severely reduced TAPSE – classic ' 'right heart failure – making Impella RP the correct targeted device.' ), 'distractors': [ ('a) TandemHeart in LA-to-femoral artery configuration', 'The standard TandemHeart configuration draws blood from the LEFT ATRIUM via transseptal puncture ' 'and returns it to the femoral artery, providing LV unloading and augmenting systemic output. ' 'It does NOT primarily support the right ventricle. A right atrial-to-femoral arterial configuration ' '(with in-line oxygenator) is a TandemHeart variant but does not reduce LV preload and increases ' 'afterload. The Protek Duo coupled with TandemHeart pump is the TandemLife option for RV support.'), ('c) A second Impella CP in the right ventricle', 'Impella CP is designed for left-sided support – it is inserted across the AORTIC valve into the ' 'left ventricle, not the right ventricle. There is no approved configuration of Impella CP for ' 'right ventricular support. Placing a left-sided Impella in the right ventricle would be incorrect ' 'and potentially catastrophic.'), ('d) Transition to ECMO only', 'ECMO provides both circulatory and oxygenation support but does NOT reduce left ventricular ' 'preload (it can actually increase LV afterload and worsen pulmonary oedema without LV venting). ' 'The contraindication for Impella RP includes respiratory failure (where ECMO would be preferred) ' 'and BIVENTRICULAR failure (where an LVAD + RV support or ECMO would be more appropriate). ' 'In isolated right heart failure without respiratory failure, Impella RP is the correct choice.'), ], 'guideline': 'RECOVER RIGHT Prospective Cohort (Anderson et al. J Heart Lung Transplant 2015): Impella RP effective for acute RV failure. FDA approved: up to 14 days. Contraindications: biventricular failure (use LVAD), respiratory failure (use ECMO).', 'learning': 'Impella RP: femoral vein → IVC inflow → PA outflow; bypasses failing RV; up to 5 L/min; 14 days. Contraindicated in biventricular failure or respiratory failure. Protek Duo (TandemLife) is an alternative RV support via right IJV → PA.', }, { 'qnum': 10, 'tag': 'DES | STENT THROMBOSIS & DAPT DURATION', 'tag_col': NAVY, 'correct_opt': 'b', 'correct_text': 'b) Aspirin continued; clopidogrel discontinuation at 8 months increases stent thrombosis risk – delay surgery until 12-month DAPT complete if possible', 'explanation': ( 'Current ACC/AHA guidelines recommend a minimum 12 months of dual antiplatelet therapy (DAPT) ' 'after DES implantation. DES-related stent thrombosis is classified as early (0-30 days), late ' '(31-365 days), and very late (>365 days). At 8 months post-DES, the patient is still within the ' 'high-risk LATE stent thrombosis window. Premature DAPT discontinuation significantly increases ' 'the risk of stent thrombosis. In a cohort study of 192 patients undergoing noncardiac surgery ' 'after PCI, the highest risk of cardiovascular events occurred in those who discontinued DAPT ' 'prematurely (30.7% vs 0%; P=0.026). Surgery within 6 weeks of stent placement is particularly ' 'high risk. Aspirin should ALWAYS be continued perioperatively. Elective surgery should ideally ' 'be deferred until 12-month DAPT is complete for DES.' ), 'distractors': [ ('a) Both aspirin and clopidogrel discontinued 7 days before surgery', 'Aspirin should NEVER be discontinued in a patient with a DES within the first 12 months (and ' 'ideally maintained indefinitely for secondary prevention). Dual discontinuation dramatically ' 'increases stent thrombosis risk. Guidelines explicitly state aspirin should be continued ' 'perioperatively in most cardiac indications.'), ('c) Clopidogrel can be safely stopped – stent thrombosis only occurs in first 30 days', 'This is a dangerous misconception. Stent thrombosis is classified as early (0-30d), LATE ' '(31-365d), and very late (>365d). Late stent thrombosis (the patient\'s current risk period) ' 'is a well-recognised and potentially fatal complication. Very late stent thrombosis (>365d) ' 'is specifically associated with DES, due to delayed endothelialisation and polymer reactions.'), ('d) Replace clopidogrel with warfarin bridging', 'Warfarin does NOT adequately prevent stent thrombosis. P2Y12 inhibition (clopidogrel, ticagrelor, ' 'prasugrel) has a distinct antiplatelet mechanism targeting ADP-mediated platelet activation at ' 'the stent surface. Vitamin K antagonists act on coagulation factors and do not substitute for ' 'P2Y12 inhibition. Heparin bridging similarly does not replace DAPT.'), ], 'guideline': 'ACC/AHA DAPT Guidelines: DES = minimum 12 months DAPT (Class I). Surgery within 6 weeks of stent = high risk (avoid if possible). Aspirin should be continued perioperatively. Kałuza GL et al. JACC 2000: catastrophic outcomes with noncardiac surgery soon after stenting.', 'learning': 'DES DAPT: 12 months minimum. Late stent thrombosis (31-365d) = real risk. Aspirin NEVER stopped. Elective surgery should wait until DAPT complete. Premature DAPT discontinuation is the leading modifiable cause of stent thrombosis.', }, { 'qnum': 11, 'tag': 'STRUCTURAL | BALLOON MITRAL VALVULOPLASTY', 'tag_col': TEAL, 'correct_opt': 'c', 'correct_text': 'c) Percutaneous balloon mitral valvuloplasty (PMBV) – treatment of choice for favourable anatomy', 'explanation': ( 'This patient satisfies all Class I criteria for PMBV: (1) symptomatic severe mitral stenosis ' '(MVA 1.2 cm², ≤1.5 cm²), (2) favourable valve morphology (pliable, non-calcified, Wilkins score ' '6 which is ≤8 = favourable), (3) absence of left atrial thrombus (excluded by TEE), and ' '(4) no more than trivial mitral regurgitation. PMBV achieves excellent results in this setting, ' 'increasing MVA from <1.0 cm² to ~2.0 cm² with 50-60% reduction in transmitral gradient. ' 'Long-term outcomes of PMBV are at least equivalent to – and in some studies superior to – ' 'closed surgical commissurotomy. PMBV avoids thoracotomy, sternotomy, and cardiopulmonary bypass ' 'while offering durable haemodynamic benefit. ACC/AHA 2014 Valve Guidelines explicitly recommend ' 'PMBV as Class I for this clinical scenario.' ), 'distractors': [ ('a) Mitral valve replacement with a mechanical prosthesis', 'MVR is indicated when PMBV is contraindicated or fails, or when there is severe calcification, ' 'significant subvalvular disease, concomitant moderate-severe MR, or left atrial thrombus that ' 'cannot be cleared. This patient has none of these contraindications. MVR subjects the patient ' 'to lifelong anticoagulation and prosthetic valve complications unnecessarily.'), ('b) Open surgical commissurotomy via median sternotomy', 'Multiple randomised trials (Ben Farhat 1998 Circulation; Turi 1991 Circulation) have shown that ' 'PMBV outcomes are equivalent to or better than open surgical commissurotomy in patients with ' 'favourable anatomy. Open surgery carries higher morbidity, longer recovery, and is not the ' 'preferred first approach when PMBV criteria are met.'), ('d) Defer intervention until MVA <1.0 cm²', 'ACC/AHA 2014 guidelines recommend intervention when MVA ≤1.5 cm² in SYMPTOMATIC patients (Class I). ' 'Waiting for MVA to fall below 1.0 cm² would expose this patient to unnecessary progression of ' 'pulmonary hypertension, right ventricular dysfunction, and atrial fibrillation. MVA ≤1.0 cm² ' 'is the threshold for intervention in ASYMPTOMATIC patients (Class IIa).'), ], 'guideline': 'ACC/AHA 2014 Valvular Heart Disease Guidelines: PMBV Class I for symptomatic severe MS (MVA ≤1.5 cm²) with favourable morphology, no LA thrombus, no significant MR. PMBV Class IIa for asymptomatic MVA ≤1.0 cm².', 'learning': 'Wilkins score ≤8 = favourable for PMBV. PMBV = treatment of choice in young patients with pliable valves. Four contraindications: LA thrombus, ≥moderate MR, severe calcification/subvalvular disease. TEE mandatory before PMBV.', }, { 'qnum': 12, 'tag': 'STRUCTURAL | ALCOHOL SEPTAL ABLATION COMPLICATION', 'tag_col': ORANGE, 'correct_opt': 'b', 'correct_text': 'b) Pre-existing LBBB increases CHB risk after ASA – ablation targets basal septum near the right bundle', 'explanation': ( 'Complete heart block (CHB) is the most common significant complication of alcohol septal ablation ' '(ASA), occurring in approximately 7-14% of patients within 5 days of the procedure, necessitating ' 'permanent pacemaker implantation. A right bundle branch block (RBBB) occurs in >40% and primary ' 'AV conduction abnormality in >50% of patients. The procedure targets the first or second septal ' 'perforating artery, causing an iatrogenic infarct of the BASAL SEPTUM. This region is close to ' 'the RIGHT BUNDLE BRANCH. In a patient with pre-existing LBBB, loss of the right bundle due to ' 'ablation results in complete heart block. Chang et al. (JACC 2003) specifically identified ' 'baseline LBBB as a predictor of CHB after ASA. A prophylactic temporary pacing wire is ' 'mandatory because transient heart block is extremely common during the procedure itself.' ), 'distractors': [ ('a) CHB is extremely rare and was not expected', 'This is incorrect. CHB requiring pacemaker is one of the most common and well-documented ' 'complications of ASA, occurring in 7-14% of patients. It is a KNOWN and EXPECTED risk, ' 'especially with pre-existing LBBB. All patients undergoing ASA should have a prophylactic ' 'temporary pacing wire placed before the procedure for this reason.'), ('c) CHB is unique to ASA and does not occur after surgical myectomy', 'CHB can also occur after surgical septal myectomy, although rates are generally lower than ' 'with ASA. The comparative data show that the procedural complication rate of ASA (including ' 'CHB) is HIGHER than surgical myectomy. However, overall survival rates are similar between ' 'the two approaches.'), ('d) Atropine and isoprenaline; block is transient in >90%', 'While TRANSIENT heart block during ASA is common (necessitating a temporary pacing wire), ' 'the COMPLETE heart block that presents days after the procedure (as in this case – day 4) ' 'is much more likely to require a permanent pacemaker. In a patient with pre-existing LBBB ' 'who develops syncope with CHB at rate 32 bpm, medical management with atropine/isoprenaline ' 'is a temporising measure only – permanent pacing is required.'), ], 'guideline': 'ACC/AHA 2011 Hypertrophic Cardiomyopathy Guidelines: ASA only for patients who are poor surgical candidates or decline surgery. Chang SM et al. JACC 2003: LBBB = predictor of CHB after ASA. Prophylactic temporary pacing wire mandatory.', 'learning': 'ASA: CHB in 7-14%, RBBB in >40%, AV block in >50%. Baseline LBBB = highest risk for CHB (right bundle targeted). Temporary pacing wire is mandatory. ASA complication rate > surgical myectomy, but survival is similar. ASA reserved for non-surgical candidates per guidelines.', }, { 'qnum': 13, 'tag': 'STRUCTURAL | PFO CLOSURE TRIALS', 'tag_col': TEAL, 'correct_opt': 'c', 'correct_text': 'c) Amplatzer PFO Occluder FDA approved; RESPECT extended + REDUCE + CLOSE: clear stroke reduction; patient is high-benefit', 'explanation': ( 'The evidence for PFO closure has evolved significantly. Early trials (CLOSURE I, PC, RESPECT) ' 'had conflicting results, and pooled analysis did not reach statistical significance on ' 'intention-to-treat analysis. However, subsequent trials with more stringent selection criteria ' 'and the Amplatzer PFO Occluder specifically showed clear benefit: RESPECT (extended follow-up, ' 'NEJM 2017), REDUCE (NEJM 2017), and CLOSE (NEJM 2017) all demonstrated significant reduction ' 'in recurrent stroke with device closure. Meta-analysis excluding CLOSURE I (device withdrawn ' 'from market) showed 5.1% vs 1.8% stroke rate (absolute risk reduction 3.3%). The FDA approved ' 'the Amplatzer PFO Occluder based on these data. This patient has the highest-benefit features: ' 'large right-to-left shunt, atrial septal aneurysm, and two prior cryptogenic strokes.' ), 'distractors': [ ('a) Pooled analysis of early trials showed significant reduction – Class I', 'This is incorrect. The INITIAL pooled analysis of CLOSURE I, PC, and RESPECT did NOT find ' 'statistically significant reduction (RR 0.66; 95% CI 0.37-1.19). It was the SUBSEQUENT trials ' '(RESPECT extended, REDUCE, CLOSE) with better patient selection that demonstrated clear benefit. ' 'PFO closure is currently Class IIa, not Class I, in most guidelines.'), ('b) CLOSURE I device remains the gold standard', 'The CLOSURE I trial used the STARFlex device which was WITHDRAWN from the market. This trial ' 'is specifically EXCLUDED from meta-analyses of current PFO closure benefit because its device ' 'is no longer available. The Amplatzer PFO Occluder is the FDA-approved device with supporting ' 'evidence from RESPECT and related trials.'), ('d) Anticoagulation with warfarin is equivalent and preferred in all patients', 'Prior evidence showed warfarin and antiplatelet therapy had similar rates of recurrent stroke. ' 'The CLOSE trial specifically compared PFO closure vs anticoagulation vs antiplatelet therapy ' 'and showed device closure was superior. Warfarin may be appropriate in some patients ' '(e.g., concomitant DVT/PE) but is NOT equivalent to device closure and is not universally ' 'preferred over closure in patients with large shunt and septal aneurysm.'), ], 'guideline': 'RESPECT Extended (NEJM 2017), REDUCE (NEJM 2017), CLOSE (NEJM 2017): PFO closure reduces recurrent stroke. Meta-analysis: ARR 3.3%. FDA approved: Amplatzer PFO Occluder. Highest benefit: large right-to-left shunt + atrial septal aneurysm.', 'learning': 'PFO trial evolution: Early pooled (borderline) → RESPECT extended + REDUCE + CLOSE (clear benefit). CLOSURE I excluded (device withdrawn). Amplatzer PFO Occluder = FDA approved. Most benefit: large shunt + septal aneurysm + cryptogenic stroke. CLOSE trial: closure superior to anticoagulation.', }, { 'qnum': 14, 'tag': 'STRUCTURAL | MitraClip COAPT TRIAL', 'tag_col': TEAL, 'correct_opt': 'b', 'correct_text': 'b) Percutaneous MitraClip – COAPT trial: reduced HF hospitalisation AND reduced all-cause mortality', 'explanation': ( 'The COAPT trial (Stone GW et al. NEJM 2018; N=614) is the pivotal trial for MitraClip in ' 'SECONDARY (functional) mitral regurgitation due to heart failure. It compared MitraClip plus ' 'guideline-directed medical therapy vs medical therapy alone in patients with HF and moderate-to-' 'severe or severe secondary MR. The MitraClip group demonstrated: (1) significantly lower rates ' 'of HF hospitalisation at 2 years (35.8% vs 67.9%; HR 0.53; P<0.001) and (2) reduced all-cause ' 'mortality (29.1% vs 46.1%; HR 0.62; P<0.001). This is distinct from the EVEREST II trial which ' 'studied PRIMARY MR and showed MitraClip was inferior to surgery for freedom from MR. The patient ' 'here has SECONDARY MR (ischaemic cardiomyopathy) with prohibitive surgical risk – COAPT scenario ' 'is the precise match.' ), 'distractors': [ ('a) Surgical mitral valve replacement – minimally invasive', 'The question explicitly states prohibitive surgical risk. Surgical options are contraindicated ' 'here. Even if surgical risk were acceptable, MVR for secondary MR in ischaemic cardiomyopathy ' 'with LVEF 28% has not been shown to improve mortality in the way COAPT showed for MitraClip.'), ('c) TAVR to reduce afterload', 'TAVR is for aortic valve disease and has no direct role in treating mitral regurgitation. ' 'While reducing afterload improves haemodynamics, there is no evidence that TAVR reduces ' 'mortality in functional MR. This is a distractor testing knowledge of appropriate indication.'), ('d) IABP as long-term circulatory support', 'IABP is a short-term bridging device, not a long-term management strategy. IABP-SHOCK II ' 'demonstrated no mortality benefit even in the acute cardiogenic shock setting. Using IABP ' 'as chronic management for secondary MR/HF has no evidence base and is not feasible.'), ], 'guideline': 'COAPT Trial (NEJM 2018): MitraClip for secondary MR + HF → reduced HF hospitalisation (35.8% vs 67.9%) and mortality (29.1% vs 46.1%) at 2 years. ACC/AHA 2014: MitraClip for NYHA III/IV, chronic severe MR, prohibitive surgical risk (Class IIa).', 'learning': 'COAPT = SECONDARY MR in HF → MitraClip beneficial (hospitalisation + mortality ↓). EVEREST II = PRIMARY MR → surgery superior for MR control but MitraClip had fewer 30-day adverse events. MitraClip mechanism: edge-to-edge Alfieri stitch via transseptal approach.', }, { 'qnum': 15, 'tag': 'CATHETER-BASED THERAPY | SVG PCI', 'tag_col': NAVY, 'correct_opt': 'b', 'correct_text': 'b) Distal embolic protection device – SAFER trial: 50% reduction in periprocedural MI during SVG PCI', 'explanation': ( 'Saphenous vein graft (SVG) lesions are characterised by degenerated, bulky, thrombotic plaques ' 'without thick fibrous caps, predisposing to significant distal embolisation during PCI. The ' 'SAFER trial (Baim DS et al. Circulation 2002) demonstrated a 50% reduction in periprocedural ' 'MI with the PercuSurge GuardWire distal occlusion protection device compared with conventional ' 'PCI during SVG intervention. Distal embolic protection devices are endorsed as Class I/IIa for ' 'SVG PCI when technically feasible. Unlike native coronary arteries (where distal protection has ' 'NOT been shown to benefit), SVG disease has strong evidence supporting embolic protection.' ), 'distractors': [ ('a) Rotational atherectomy to debulk SVG plaque', 'Rotational atherectomy is used as an enabling device for CALCIFIED NATIVE coronary artery ' 'stenoses that are undilatable. It is NOT indicated for SVG PCI. Rotational atherectomy in ' 'a degenerated SVG would risk embolisation of friable thrombus and plaque material and ' 'catastrophic distal embolisation. This is contraindicated in SVG disease.'), ('c) Routine aspiration thrombectomy – Class I for SVG PCI with thrombus', 'Routine aspiration thrombectomy in SVG PCI is NOT Class I. The evidence supports distal ' 'embolic protection (SAFER trial) not thrombectomy as the primary adjunctive strategy. ' 'Additionally, the TOTAL trial\'s caution about routine thrombectomy applies broadly. ' 'The VEGAS-II trial compared thrombectomy to fibrinolysis in SVG and showed thrombectomy ' 'reduced 30-day MACE, but distal protection with the GuardWire is the preferred strategy.'), ('d) Manual balloon dilation without stenting', 'Balloon dilation without stenting in SVG PCI leaves a significant risk of elastic recoil, ' 'residual stenosis, and acute closure. Stent placement is standard of care in SVG PCI. ' 'The question of stent type (BMS vs DES) in SVG is debated – meta-analysis of 6 RCTs showed ' 'no significant difference in mortality or MACE. Balloon dilation alone would not address ' 'the high-grade stenosis or the embolisation risk.'), ], 'guideline': 'SAFER Trial (Circulation 2002): PercuSurge GuardWire → 50% reduction in periprocedural MI during SVG PCI. ACC/AHA Box 56.2 Class I: distal embolic protection when technically feasible for SVG PCI. Note: DES vs BMS in SVG – meta-analysis shows no significant difference in mortality/MACE.', 'learning': 'SVG PCI hallmark: use distal embolic protection (SAFER trial). Not beneficial in native coronary PCI. Rotational atherectomy is for calcified NATIVE lesions – avoid in SVG. DES vs BMS in SVG: no clear winner in meta-analysis of 6 RCTs.', }, { 'qnum': 16, 'tag': 'COMPLICATIONS | CIN PREVENTION', 'tag_col': ORANGE, 'correct_opt': 'b', 'correct_text': 'b) Pre-hydration and post-hydration with isotonic normal saline – strongest evidence for CIN prevention', 'explanation': ( 'Contrast-induced nephropathy (CIN) is associated with adverse clinical outcomes including reduced ' 'survival. Hydration with isotonic normal saline (0.9% NaCl) before and after the procedure ' 'remains the ONLY intervention with consistent, high-quality evidence for reducing CIN. ' 'The mechanism is volume expansion, dilution of contrast, and maintenance of renal tubular flow. ' 'All other proposed interventions (N-acetylcysteine, forced diuresis, fenoldopam, dopamine, ' 'calcium antagonists, atrial natriuretic peptide) have NOT been shown to provide benefit in ' 'well-designed clinical trials and are not routinely recommended. Minimising contrast volume, ' 'using iso-osmolar or low-osmolar contrast agents, and stopping nephrotoxic drugs are additional ' 'strategies with supporting evidence.' ), 'distractors': [ ('a) N-acetylcysteine (NAC)', 'NAC was historically used based on an early pilot study (Tepel et al. NEJM 2000) suggesting ' 'benefit. However, multiple subsequent large RCTs have shown NO significant benefit of NAC ' 'in preventing CIN. The ACT trial (Lancet 2011) – the largest RCT of NAC for CIN prevention ' '(N=2308) – showed no reduction in CIN or need for dialysis. ACC/AHA guidelines state ' '"routine use is not recommended." This is a HIGH-YIELD exam reversal.'), ('c) Fenoldopam infusion', 'Fenoldopam is a selective dopamine-1 receptor agonist that promotes renal vasodilation. ' 'Despite theoretical benefit, the CONTRAST trial (Marenzi et al.) and meta-analyses have ' 'not consistently demonstrated a clinically meaningful reduction in CIN with fenoldopam, ' 'and it carries risk of systemic hypotension. It is not recommended in routine practice.'), ('d) Forced diuresis with furosemide + mannitol', 'Forced diuresis with furosemide and mannitol has been specifically studied and shown to be ' 'INEFFECTIVE or potentially HARMFUL. Solomon et al. (NEJM 1994) showed that forced diuresis ' 'was inferior to saline hydration alone in preventing contrast-induced renal function decline. ' 'Volume depletion from aggressive diuresis may worsen contrast-induced renal injury.'), ], 'guideline': 'ACC/AHA PCI Guidelines: CIN prevention = isotonic saline hydration (Class I). N-acetylcysteine: NOT recommended (routine use; no consistent benefit in large RCTs). Forced diuresis/mannitol/furosemide: NOT effective. Risk score: Mehran CIN score identifies patients at >50% risk.', 'learning': 'CIN prevention: saline hydration = ONLY proven strategy. NAC = NOT routinely recommended (ACT trial). No benefit from: furosemide, mannitol, dopamine, calcium antagonists, ANP. Mehran score predictors: hypotension, IABP, CHF, CKD, DM, age >75, anaemia, contrast volume.', }, { 'qnum': 17, 'tag': 'RESTENOSIS | MECHANISM & DES', 'tag_col': GREEN, 'correct_opt': 'b', 'correct_text': 'b) Smooth muscle cell proliferation & neointimal hyperplasia; DES elutes anti-proliferative drugs inhibiting the cell cycle', 'explanation': ( 'In-stent restenosis is primarily driven by smooth muscle cell (SMC) proliferation and neointimal ' 'hyperplasia. After balloon dilation and stent deployment, the acute arterial injury triggers: ' '(1) platelet aggregation and inflammatory cell adhesion, (2) release of mitogens (e.g., PDGF, ' 'FGF) that switch SMCs from contractile to PROLIFERATIVE phenotype, (3) matrix metalloproteinase-' 'mediated SMC migration from media to intima, and (4) neointimal hyperplasia. This, combined with ' 'elastic recoil (negative remodelling), causes luminal renarrowing. DES elute anti-proliferative ' 'drugs: sirolimus/everolimus (limus family – cytostatic, anti-inflammatory, anti-migratory) or ' 'paclitaxel (cytocidal – arrests cell cycle in G2/M phase). These drugs reduce late lumen loss ' 'and restenosis from ~30% (BMS) to <10% (DES).' ), 'distractors': [ ('a) Stent fracture → thrombosis; DES prevents fracture through polymer flexibility', 'Stent fracture is a recognised cause of STENT THROMBOSIS and a potential contributor to ' 'restenosis in rare cases, but it is NOT the primary mechanism of typical in-stent restenosis. ' 'DES action is through drug elution (anti-proliferative), not through structural prevention ' 'of fracture. Newer DES designs do address strut thickness and fracture resistance, but this ' 'is not the mechanism of restenosis prevention.'), ('c) Macrophage-mediated plaque rupture; DES stabilises plaque with anti-inflammatory coating', 'Plaque rupture and macrophage activity relate to ACS/unstable lesion pathophysiology, not ' 'to in-stent restenosis. While limus-family drugs do have anti-inflammatory properties, ' 'the dominant mechanism by which DES prevents restenosis is anti-SMC proliferative activity, ' 'not plaque stabilisation.'), ('d) Elastic recoil; DES stent design prevents radial collapse', 'Elastic recoil (20-30% of initial gain lost immediately after balloon dilation) is a ' 'component of restenosis. However, this is addressed equally by BMS and DES through mechanical ' 'scaffolding – it is NOT the distinguishing advantage of DES. DES specifically reduces LATE ' 'lumen loss (6-8 months) through drug action on SMC proliferation, which is the main mechanism ' 'of restenosis reduction beyond what BMS already achieves through acute gain.'), ], 'guideline': 'Kuntz RE et al. JACC 1993: Late lumen loss follows Gaussian distribution; 50% of initial gain lost by 6-8 months. DES approved 2004: sirolimus (Cypher) and paclitaxel (TAXUS). DES reduces restenosis from 30% to <10%.', 'learning': 'Restenosis mechanism: SMC proliferation + neointimal hyperplasia + elastic recoil. BMS addresses recoil (acute gain). DES addresses SMC proliferation (late loss). BMS restenosis: 12-50%. DES restenosis: <10%. Predictors: DM, small vessels, long lesions, bifurcations, prior restenosis.', }, { 'qnum': 18, 'tag': 'CIN | RISK PREDICTION – MEHRAN SCORE', 'tag_col': ORANGE, 'correct_opt': 'b', 'correct_text': 'b) Hypotension + IABP + CHF + CKD + DM + age 78 + anaemia + large contrast volume = HIGHEST risk combination', 'explanation': ( 'The Mehran CIN risk score identifies patients at highest risk for contrast-induced nephropathy. ' 'The significant predictors included in the score are: (1) Hypotension requiring IABP support, ' '(2) CHF, (3) Age >75 years, (4) Anaemia, (5) Diabetes mellitus, (6) Contrast volume, ' '(7) Chronic kidney disease (serum creatinine >1.5 mg/dL or eGFR <60), (8) IABP use. ' 'Each factor carries a point value; higher scores correlate with markedly higher CIN risk. ' 'Patients at highest risk can have a CIN risk exceeding 50% and a dialysis risk of 15%+ . ' 'Option b) combines ALL major Mehran score predictors: IABP, CHF, CKD (eGFR 28), DM, age 78 ' '(>75), anaemia, and large contrast volume – this patient is at the highest possible risk.' ), 'distractors': [ ('a) Male, age 45, normal renal function, 80 mL contrast', 'This represents a LOW-RISK patient. Age 45 (not >75), normal renal function (no CKD), ' 'no diabetes, no CHF or haemodynamic compromise. A low contrast volume of 80 mL in a young ' 'patient with normal kidneys carries minimal CIN risk. Male sex is not a Mehran risk factor.'), ('c) Hypertension, hyperlipidaemia, smoking, stable angina, preserved renal function', 'These are general cardiovascular risk factors but are NOT components of the Mehran CIN risk ' 'score. The Mehran score specifically identifies renal, haemodynamic, and metabolic risk factors ' 'rather than traditional atherosclerotic risk factors.'), ('d) Female, age 55, mild obesity, normal creatinine, 100 mL contrast', 'Normal renal function is the strongest protector against CIN. Despite 100 mL contrast, ' 'a patient aged 55 with normal kidneys, no CHF, no DM, and no haemodynamic compromise has ' 'low CIN risk. Contrast volume alone in a low-risk patient does not confer high risk.'), ], 'guideline': 'Mehran R et al. JACC 2004: Mehran CIN risk score (development and validation). Factors: hypotension, IABP, CHF, CKD, DM, age >75, anaemia, contrast volume. Highest risk: >57 points → CIN risk >57%, dialysis risk ~13%.', 'learning': 'Mehran CIN score = 8 predictors: Hypotension, IABP, CHF, CKD, DM, Age >75, Anaemia, Volume of contrast. Mnemonic: "HICA-DAAV" or just remember the combo of haemodynamic instability + renal impairment + metabolic factors = highest risk.', }, { 'qnum': 19, 'tag': 'STRUCTURAL | ASD – PATIENT SELECTION', 'tag_col': TEAL, 'correct_opt': 'b', 'correct_text': 'b) Percutaneous transcatheter device closure appropriate – suitable anatomy, Qp:Qs ≥1.5, RV dilatation', 'explanation': ( 'This patient has a secundum ASD with: (1) adequate rim tissue on all sides (6 mm, required minimum ' 'is ≥4-5 mm), (2) defect size 22 mm (within percutaneous closure range, stretched diameter <38 mm ' 'required), (3) haemodynamically significant shunt with Qp:Qs 1.8 (threshold is ≥1.5), (4) right ' 'ventricular dilatation (structural consequence of left-to-right shunt), and (5) no pulmonary ' 'hypertension (no contraindication). These are standard indications for percutaneous closure. ' 'Observational studies comparing percutaneous vs surgical ASD closure show comparable procedural ' 'success and long-term mortality, with reduced complications and shorter hospital stay with ' 'percutaneous approaches. Percutaneous closure with an Amplatzer-type device is the preferred ' 'strategy for suitable secundum ASDs.' ), 'distractors': [ ('a) Surgical closure mandatory as percutaneous only for defects <10 mm', 'There is no such restriction of percutaneous closure to defects <10 mm. Percutaneous closure ' 'is appropriate for secundum ASDs with stretched diameter <38 mm and adequate rim tissue (≥4 mm). ' 'Surgical closure is needed for: ostium primum, sinus venosus, coronary sinus defects, inadequate ' 'rims (<4 mm on any critical side), or stretched diameter >38 mm.'), ('c) Medical management with pulmonary vasodilators preferred', 'Pulmonary vasodilators are used for established pulmonary arterial hypertension as a result of ' 'long-standing shunt. In this patient without pulmonary hypertension, closure is indicated and ' 'preventive. Deferral with medical management would allow progressive RV volume overload, pulmonary ' 'hypertension development, atrial arrhythmias, and paradoxical embolism to develop over time.'), ('d) Closure not indicated as patient is asymptomatic', 'Haemodynamic indications (Qp:Qs ≥1.5) and structural consequences (RV dilatation) justify ' 'closure regardless of symptom status. ACC/AHA 2008 Adult Congenital Heart Disease guidelines ' 'recommend closure when Qp:Qs ≥1.5 or when there is right heart volume overload or embolism. ' 'Waiting for symptoms may result in irreversible pulmonary hypertension.'), ], 'guideline': 'ACC/AHA 2008 Adult Congenital Heart Disease Guidelines: ASD closure indicated when Qp:Qs ≥1.5, RV dilatation, or embolism. Percutaneous suitable for secundum ASD with stretched diameter <38 mm, rim ≥4-5 mm. NOT suitable: ostium primum, sinus venosus, coronary sinus, inadequate rim.', 'learning': 'ASD closure indications: Qp:Qs ≥1.5, RV volume overload, embolism, arrhythmia. Percutaneous NOT suitable for: ostium primum, sinus venosus, coronary sinus defects, stretched diameter >38 mm, rim <4-5 mm. Scuba divers with decompression sickness + ASD = consider closure.', }, { 'qnum': 20, 'tag': 'PERIOPERATIVE | PCI + NON-CARDIAC SURGERY', 'tag_col': NAVY, 'correct_opt': 'b', 'correct_text': 'b) Surgery should be deferred; surgery within 6 weeks of stent placement is high-risk – premature DAPT cessation amplifies stent thrombosis', 'explanation': ( 'Surgery within 6 weeks of stent placement (any stent – BMS or DES) is associated with a ' 'significantly higher incidence of adverse events including death and MI and should be avoided ' 'when possible (Kałuza et al. JACC 2000). This patient received a DES only 4 weeks ago and has ' 'now also stopped clopidogrel prematurely (5 days ago for elective surgery), further amplifying ' 'risk. In a cohort study of 192 patients, the highest risk of cardiovascular events in the ' 'postoperative period occurred in those who discontinued DAPT prematurely (30.7% vs 0%; P=0.026). ' 'The mechanism includes the hypercoagulable state induced by surgery combined with bare stent ' 'struts still undergoing endothelialisation. Elective inguinal hernia repair should be deferred ' 'until at least 12 months post-DES with completion of DAPT. Aspirin should be restarted ' 'immediately. ACC/AHA recommends PCI only when revascularisation benefit is independent of surgery.' ), 'distractors': [ ('a) Surgery is safe; DES thrombosis negligible by 4 weeks', 'This statement is false and potentially fatal. DES stent thrombosis occurs throughout the ' '12-month DAPT window (early, late, and very late). The risk is particularly high in the first ' '6 weeks post-implantation when endothelialisation is incomplete, and doubly so when DAPT is ' 'discontinued. "Negligible by 4 weeks" has no evidence base – this is the highest risk period.'), ('c) Prophylactic IABP during surgery to prevent ischaemia', 'Prophylactic IABP during noncardiac surgery is not a standard or evidence-based practice for ' 'stent-related perioperative ischaemia risk. The BCIS-1 trial found that elective IABP before ' 'high-risk PCI (not noncardiac surgery) had no 28-day benefit. There is no evidence supporting ' 'prophylactic IABP for perioperative coronary protection in patients with recent stents.'), ('d) Bridging with IV heparin adequately protects against stent thrombosis', 'IV heparin bridging does NOT substitute for DAPT (P2Y12 inhibition) for stent thrombosis ' 'prevention. Anticoagulation targets the coagulation cascade while DAPT targets ADP-mediated ' 'platelet activation – the primary mechanism of stent thrombosis. Multiple studies have shown ' 'that heparin bridging does not prevent stent thrombosis when P2Y12 inhibitors are discontinued.'), ], 'guideline': 'ACC/AHA PCI Guidelines: Avoid surgery <6 weeks post-stent (high risk). DES: minimum 12 months DAPT. ACC/AHA 2007 Perioperative Guidelines: cardiac testing before noncardiac surgery only if it will change management. Kałuza et al. JACC 2000: catastrophic outcomes with noncardiac surgery soon after stent.', 'learning': 'Surgery timing post-stent: <6 weeks = very high risk; 6 weeks to 12 months (DES) = still elevated risk if DAPT incomplete. Aspirin NEVER stopped. Premature DAPT discontinuation = #1 modifiable cause of stent thrombosis. No role for heparin bridging for stent thrombosis prevention.', }, ] # ════════════════════════════════════════════════════════════════ # BUILD PDF3 # ════════════════════════════════════════════════════════════════ doc3 = SimpleDocTemplate( '/home/daytona/workspace/ini_ss_ch56/PDF3_Answer_Key_Explanations.pdf', pagesize=A4, leftMargin=1.8*cm, rightMargin=1.8*cm, topMargin=1.8*cm, bottomMargin=1.8*cm ) story3 = [] # Cover cov = Table([[ Paragraph('INI SS CET – CARDIOTHORACIC & VASCULAR SURGERY', SP('Sub')), Paragraph('CHAPTER 56: INTERVENTIONAL CARDIOLOGY', SP('Title')), Paragraph('Answer Key | Detailed Explanations | Distractor Analysis | 20 Questions', SP('Sub')), ]], colWidths=[17*cm]) cov.setStyle(TableStyle([ ('BACKGROUND',(0,0),(-1,-1),NAVY), ('TOPPADDING',(0,0),(-1,-1),12),('BOTTOMPADDING',(0,0),(-1,-1),12), ('LEFTPADDING',(0,0),(-1,-1),8), ('SPAN',(0,0),(-1,-1)), ])) story3.append(cov) story3.append(Spacer(1,6)) # Quick answer key summary table story3.append(colored_hdr('QUICK ANSWER KEY SUMMARY', TEAL)) story3.append(Spacer(1,3)) aq_data = [['Q', 'Answer', 'Topic']] for a in answers: aq_data.append([str(a['qnum']), a['correct_opt'].upper(), a['tag']]) from reportlab.platypus import Table as RLTable aq_t = RLTable(aq_data, colWidths=[1.2*cm, 2*cm, 13.8*cm]) aq_ts = TableStyle([ ('BACKGROUND',(0,0),(-1,0), TEAL), ('TEXTCOLOR',(0,0),(-1,0), white), ('FONTNAME',(0,0),(-1,0),'Helvetica-Bold'), ('FONTSIZE',(0,0),(-1,-1),8.5), ('ROWBACKGROUNDS',(0,1),(-1,-1),[white, HexColor('#f0f4fb')]), ('GRID',(0,0),(-1,-1),0.3,colors.grey), ('TOPPADDING',(0,0),(-1,-1),2), ('BOTTOMPADDING',(0,0),(-1,-1),2), ('LEFTPADDING',(0,0),(-1,-1),4), ]) aq_t.setStyle(aq_ts) story3.append(aq_t) story3.append(Spacer(1,8)) # Detailed explanations for a in answers: blk = [] # Question header bar hdr_p = Paragraph(f"Q{a['qnum']} | {a['tag']}", SP('QHdr')) hdr_t = Table([[hdr_p]], colWidths=[17*cm]) hdr_t.setStyle(TableStyle([ ('BACKGROUND',(0,0),(-1,-1), a['tag_col']), ('TOPPADDING',(0,0),(-1,-1),5),('BOTTOMPADDING',(0,0),(-1,-1),5), ('LEFTPADDING',(0,0),(-1,-1),8), ])) blk.append(hdr_t) # Correct answer ca_p = Paragraph(f"✔ CORRECT ANSWER: ({a['correct_opt'].upper()}) {a['correct_text']}", SP('Correct')) ca_t = Table([[ca_p]], colWidths=[17*cm]) ca_t.setStyle(TableStyle([ ('BACKGROUND',(0,0),(-1,-1), LTGREEN), ('TOPPADDING',(0,0),(-1,-1),5),('BOTTOMPADDING',(0,0),(-1,-1),5), ('LEFTPADDING',(0,0),(-1,-1),8), ('RIGHTPADDING',(0,0),(-1,-1),8), ('BOX',(0,0),(-1,-1),0.5, GREEN), ])) blk.append(ca_t) blk.append(Spacer(1,3)) # Explanation exp_lbl = Paragraph('EXPLANATION', SP('Label')) exp_lt = Table([[exp_lbl]], colWidths=[4*cm]) exp_lt.setStyle(TableStyle([('BACKGROUND',(0,0),(-1,-1),NAVY), ('TOPPADDING',(0,0),(-1,-1),2),('BOTTOMPADDING',(0,0),(-1,-1),2), ('LEFTPADDING',(0,0),(-1,-1),6)])) exp_bp = Paragraph(a['explanation'], SP('Body')) exp_bt = Table([[exp_bp]], colWidths=[17*cm]) exp_bt.setStyle(TableStyle([('BACKGROUND',(0,0),(-1,-1), HexColor('#f0f4fb')), ('TOPPADDING',(0,0),(-1,-1),5),('BOTTOMPADDING',(0,0),(-1,-1),5), ('LEFTPADDING',(0,0),(-1,-1),8),('RIGHTPADDING',(0,0),(-1,-1),8), ('BOX',(0,0),(-1,-1),0.3,colors.grey)])) blk.append(exp_lt) blk.append(exp_bt) blk.append(Spacer(1,4)) # Distractors dist_lbl = Paragraph('DISTRACTOR ANALYSIS', SP('Label')) dist_lt = Table([[dist_lbl]], colWidths=[4.5*cm]) dist_lt.setStyle(TableStyle([('BACKGROUND',(0,0),(-1,-1),RED), ('TOPPADDING',(0,0),(-1,-1),2),('BOTTOMPADDING',(0,0),(-1,-1),2), ('LEFTPADDING',(0,0),(-1,-1),6)])) blk.append(dist_lt) for opt_txt, explanation in a['distractors']: d_rows = [ [Paragraph(f"✗ {opt_txt}", SP('Dist'))], [Paragraph(explanation, SP('DistB'))], ] d_t = Table(d_rows, colWidths=[17*cm]) d_t.setStyle(TableStyle([ ('BACKGROUND',(0,0),(0,0), LTRED), ('BACKGROUND',(0,1),(0,1), white), ('TOPPADDING',(0,0),(-1,-1),3),('BOTTOMPADDING',(0,0),(-1,-1),3), ('LEFTPADDING',(0,0),(-1,-1),8),('RIGHTPADDING',(0,0),(-1,-1),8), ('BOX',(0,0),(-1,-1),0.3,RED), ('LINEBELOW',(0,0),(-1,-1),0.3,colors.lightgrey), ])) blk.append(d_t) blk.append(Spacer(1,1)) blk.append(Spacer(1,3)) # Guideline gl_rows = [[Paragraph('RELEVANT GUIDELINE / TRIAL', SP('Label')), Paragraph(a['guideline'], SP('Body'))]] gl_t = Table(gl_rows, colWidths=[4.5*cm, 12.5*cm]) gl_t.setStyle(TableStyle([ ('BACKGROUND',(0,0),(0,0), ORANGE), ('BACKGROUND',(0,0),(1,0), LTYELLOW), ('TOPPADDING',(0,0),(-1,-1),4),('BOTTOMPADDING',(0,0),(-1,-1),4), ('LEFTPADDING',(0,0),(-1,-1),6),('RIGHTPADDING',(0,0),(-1,-1),6), ('VALIGN',(0,0),(-1,-1),'TOP'), ('BOX',(0,0),(-1,-1),0.3,ORANGE), ])) blk.append(gl_t) blk.append(Spacer(1,3)) # Learning point lp_rows = [[Paragraph('LEARNING POINT', SP('Label')), Paragraph(a['learning'], SP('Body'))]] lp_t = Table(lp_rows, colWidths=[4.5*cm, 12.5*cm]) lp_t.setStyle(TableStyle([ ('BACKGROUND',(0,0),(0,0), GREEN), ('BACKGROUND',(0,0),(1,0), LTGREEN), ('TOPPADDING',(0,0),(-1,-1),4),('BOTTOMPADDING',(0,0),(-1,-1),4), ('LEFTPADDING',(0,0),(-1,-1),6),('RIGHTPADDING',(0,0),(-1,-1),6), ('VALIGN',(0,0),(-1,-1),'TOP'), ('BOX',(0,0),(-1,-1),0.3,GREEN), ])) blk.append(lp_t) blk.append(HRFlowable(width='100%', thickness=0.8, color=NAVY, spaceAfter=8, spaceBefore=6)) for e in blk: story3.append(e) doc3.build(story3) print('PDF3 done') PYEOF echo "Exit: $?"

ls -lh /home/daytona/workspace/ini_ss_ch56/ 2>/dev/null